PREM PONKA CURRICULUM VITAE - Univerzita Karlova · PREM PONKA CURRICULUM VITAE Place of Birth: Prague, Czechoslovakia Matial Status: Married, 2 children Citizenship: Canadian EDUCATION

PREM PONKA

CURRICULUM VITAE Place of Birth: Prague, Czechoslovakia Matial Status: Married, 2 children Citizenship: Canadian EDUCATION General: 1947-1958 Primary and Secondary School, Prague Medical: 1958-1964 Charles' University School of Medicine, Prague Research: 1961-1968 Department of Pathophysiology, Charles' University School of Medicine, Prague DEGREES MD 1964 Charles' University, Prague PhD 1969 Charles' University, Prague (Physiology and Pathophysiology) CLINICAL EXPERIENCE 1965-1966 Army Hospital, Bedrichov, Czechoslovakia (Medical Officer) TEACHING EXPERIENCE 1961-1964 Demonstrator in Pathophysiology, Charles' University School of

Medicine, Prague 1964-1968 Lecturer in Pathophysiology, Charles' University School of Medicine,

Prague 1968-1979 Assistant Professor of Experimental Medicine, Charles' University School

of Medicine, Prague 1979-1987 Associate Professor of Physiology, McGill University, Montreal, QC 1983-1987 Associate Professor of Medicine, McGill University, Montreal, QC 1987-present Professor of Physiology and Medicine, McGill University, Montreal, QC

Prem Ponka

2

RESEARCH EXPERIENCE 1964-1968 Research Assistant, Institute of Pathological Physiology,

Charles' University School of Medicine, Prague 1968-1979 Research Associate, Institute of Pathological Physiology,

Charles' University School of Medicine, Prague 1980 Research Associate, Division of Hematology, Department of

Medicine, McGill University, Montreal, QC 1980-1984 Associate Investigator, Lady Davis Institute for Medical Research of the

Sir Mortimer B. Davis - Jewish General Hospital, Montreal, QC 1984-present Staff Investigator, Lady Davis Institute for Medical Research of the Sir

Mortimer B. Davis - Jewish General Hospital, Montreal, QC 1987-1988 Visiting Professor, Laboratoire de Génétique Moléculaire, Faculté de

Médecine Xavier Bichat, Université de Paris VII, Paris, France AREAS OF RESEARCH INTEREST 1. Cellular iron metabolism

- Effect of inflammatory cytokines on iron metabolism - Role of iron in cell proliferation - Role of iron in free radical formation - Role of nitric oxide in cellular iron metabolism

2. Development of new iron chelators of significance to:

- Iron overload - Inhibition of free radical reactions - Neoplastic cell replication

3. Erythroid differentiation 4. Heme synthesis regulation AWARDS AND HONORS 1980-1983 Fraser Associateship (renewed 1983-1986) 1980 Grant-in-Aid from Faculty of Graduate Studies and Research, McGill University

Prem Ponka

3

AWARDS AND HONORS (continued) 1980-1981 (Renewed 1982-1985, 1986-1987 and 1988-1990, 1990-1992, 1992-1995, 1995-

1998, 1998-2001, 2001-2006,2006-2011) MRC/CIHR Research Grant "Chelation, mobilization, and metabolism of storage iron"

1982 MRC Major Equipment Grant 1982-1992 MRC Research Grant "Transferrin and intracellular iron metabolism" 1987-1988 MRC Biotechnology Retraining Award 1987-1989 The Cancer Research Society Inc. Research Grant "Ferritin gene expression in

transformed cells" 1992-present American Men and Women of Science 1993 Canadian Porphyria Foundation, Advisory Board, Member 1994-1999 NIH (subcontract) "Mitochondrial iron metabolism" 1994-1999 Member of the Center of Excellence in Molecular Hematology, The University of

Utah, sponsored by the NIH 1995 Member of Steering Committee for the International Conferences on Proteins of

Iron Metabolism 1996-1999 (Renewed 1999-2001; 2001-2005) MRC/CIHR Research Grant "The effect of

redox species of nitrogen monoxide on intracellular iron metabolism" 1996-1999 Scientific Subcommittee on Iron and Heme, American Society of Hematology,

Chairman 1996-2001 (Renewed 2001-2005; 2005-2010) MRC/CIHR Research Grant "Regulation of

iron metabolism and heme synthesis in erythroid cells" 1997-2000 Co-chairman, East Coast Iron Club 1998 Anniversary Medal of Charles University (650 years), Prague, for outstanding

Research 1998 Raine Visiting Professorship in Physiology, The University of Western Australia 1998-present Canadian Hemochromatosis Society, Advisory Board, Member

Prem Ponka

4

AWARDS AND HONORS (continued) 1999-present Scientific Advisory Committee, Institute of Hematology and Blood Transfusion,

Prague, Visiting Member 2001 24th International Congress of Physiological Sciences, Christ Church, New

Zealand, Moderator of the Synthesium on Iron Metabolism 2000-2002 Scientific Committee on Iron and Heme, American Society of Hematology,

Member 2003-2005 International Biolron Society (IBIS), Director 2005 Thalassemia Foundation of Canada, Medical Advisory Board, Member 2005 International Congress on Iron Metabolism (BioIron 2005), Prague, Chairman (www.bioiron2005.cz) 2005-2008 Scientific Committee on Iron and Heme, American Society of Hematology,

Member 2006 Medal for Merit, Faculty of Medicine, Charles University, Prague 2007-2011 International Biolron Society (IBIS), Director 2007 Award for Excellence in Medical Research, Jewish General Hospital, Montréal

Prem Ponka

5

ADMINISTRATIVE RESPONSIBILITIES 1981-present Coordinator of course on "Physiology of Blood II" (512-516B). 1982-1986 & Graduate Students Admission and Advisory Committee (Department 1992-present of Physiology), member. 1982-1985 Graduate Faculty Council, McGill University, member. 1983-1987 Co-director (together with Dr. B. Cooper) of "Basic Science Options" course on “Hematology” for the 4th year medical students. 1984-1985 & Co-director of "Graduate Seminar", Physiology 690 A/B. 1986-1987 1985-1987 & Responsible for organizing invited guests' seminars at the 1989-1999 Lady Davis Institute. 1988-1993 Search Committee for recruitment of Molecular Biologists, Department of

Physiology, member. 1988-present Canadian Porphyria Foundation, Advisory Board, member. 1989-1990 Search Committee for recruitment of the Chief of the Department of

Medicine, Sir Mortimer B. Davis - Jewish General Hospital, member. 1989-present Organization of McGill University-Charles University (Prague) scientific

exchanges. 1993-present Academic Advisory Committee, Sir Mortimer B. Davis - Jewish General

Hospital, member. 1993-present Graduate Students' Advisor, Department of Medicine, McGill University. 1993-present Canadian Hemochromatosis Society, Advisory Board, member. 1994-2000 Executive Committee of the Division of Experimental Medicine, McGill

University, member. 1996-present Scientific Advisory Council, Biomedical Frontiers, Inc., Minneapolis,

MN. 2001-2004 McGill University Senate, member. 2004-present Thalassemia Foundation of Canada, Advisory Committee, member. 2005-present Scientific Council, Third Faculty of Medicine, Charles University, Prague.

Prem Ponka

6

SERVICE FOR GRANTING AGENCIES 1988-present Medical Research Council of Canada, external reviewer. 1988 NIH Hematology Study Section, Ad Hoc Member: Site visit to

University of South Alabama, Alabama. 1990 Manitoba Health Research Council, external reviewer. 1990 NIH Hematology Study Section, special reviewer at the October 24-26

Meeting. 1990-present FRSQ, external reviewer. 1991 British Columbia Health Care Research Foundation, external reviewer. 1991 Heart and Stroke Foundation of Canada, external reviewer. 1990-1994 NIH Hematology Study Section (Subcommittee 2), Division of Research

Grants, member. 1991 Grant Agency of the Czech Republic, external reviewer. 1992 National Science Foundation (U.S.A.), external reviewer. 1993 Department of Veterans Affairs, U.S.A. 1994 Natural Sciences and Engineering Research Council of Canada 1994-preent Member of the NIH Reviewer's Reserve 1994 International Human Frontier Science Program, Strasbourg 1994 The Hospital for Sick Children Foundation, Toronto, Ontario 1995 National Cancer Institute (USA), Special Emphasis Panel, Member 1996-2000 "Pharmaceutical Sciences" Grants Committee, Medical Research Council

of Canada, Member 1996-2000 Bayer/Canadian Red Cross Society R & D Fund, external reviewer 1997 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) -

SBIR - Phase I Contract Review, member 1997 International Foundation for Science, Stockholm, Sweden 1998-present Alberta Heritage Foundation for Medical Research, External Reviewer.

Prem Ponka

7

Services for Granting Agencies (continued) 1998-present Research Grants Council, Hong Kong, External Reviewer 1999 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) -

SBIR - Phase II Contract Review, member 2001 Philip Morris External Research Program 2005 CIHR – Doctoral Research Awards 2006 CIHR – Fellowship Awards 2006 Reviewer of a K08 Grant, NIDDK, National Institutes of Health,

Bethesda, MD 2007 Member of the Erythrocyte and Leukocyte Study Section, National

Institutes of Health, Bethesda, MD 2008 Member of the Erythrocyte and Leukocyte Study Section, National

Institutes of Health, Bethesda, MD ORGANIZATION OF INTERNATIONAL CONFERENCES 1970 International Conference on the "Regulation of Erythropoiesis and

Hemoglobin Synthesis", Prague, Czechoslovakia. 1975 International Conference on the "Regulation of Stem Cell Proliferation

and Differentiation", Prague, Czechoslovakia. 1980 "International Symposium on Iron Overload", Montreal, Canada

(a satellite Symposium to the Eighteenth Congress of the International Society of Hematology).

1987 "Eighth International Conference on Proteins of Iron Transport and

Storage", Chateau Montebello, Quebec, Canada. 1994 Twenty-Fifth Congress of the International Society of Hematology,

Cancun, Mexico, organization of a "Symposium on Iron Metabolism". 2000 Symposium on “Iron Metabolism”, 6th International World Conference for

Biomedical Sciences (INABIS 2000), February 14-25, 2000. 2001 “Synthesium of Iron Metabolism”, Twenty Fourth International Congress

of Physiological Sciences, Christchurch, New Zealand. 2005 “International Congress on Iron Metabolism (Biolron 2005)”, Prague,

Czech Republic.

Prem Ponka

8

2007 “Fifth Canadian Oxidative Stres Consortiam Meeting”, Montreal, QC,

May 4-6, 2007. CONSULTING 2007 F. Hoffmann-La Roche Ltd., Basel, Switzerland. MEMBERSHIPS American Society for Hematology American Society for Biochemistry and Molecular Biology Canadian Physiological Society Canadian Society for Clinical Investigation European Iron Club International BioIron Society International Society of Experimental Hematology International Society of Hematology Nitric Oxide Society

Prem Ponka

9

PUBLICATIONS (* denotes a book, book chapter, or a contribution to a symposium proceeding) 1. Ponka P, Neuwirt J, Prchal J. Heme synthesis during impaired globin synthesis. Folia

Hematol (Leipzig) 90: 117-119, 1968. 2. Neuwirt J, Borova J, Ponka P. The effects of heme and iron on haemoglobin A and F

synthesis in human cord blood. FEBS Lett 1: 209-210, 1968. 3. Ponka P. Regulation of iron supply for hemoglobin synthesis. Cs Fysiol 18: 243-261,

1969. 4. Ponka P, Neuwirt J. Regulation of iron entry into reticulocytes. I. Feedback inhibitory

effect of heme on iron entry into reticulocytes and on heme synthesis. Blood 33: 690-707, 1969.

5. Neuwirt J, Ponka P, Borova J. The role of heme in the regulation of δ-aminolevulinic

acid and heme synthesis in rabbit reticulocytes. Eur J Biochem 9: 36-41, 1969. 6. Neuwirt J, Ponka P, Borova J, Prchal JF. The problems of reduced heme synthesis in

reticulocytes with impaired globin synthesis. Blut 19: 17-27, 1969. 7. Ponka P, Neuwirt J. The use of reticulocytes with high non-haem iron pool for studies of

regulation of haem synthesis. Brit J Haematol 19: 593-604, 1970. 8. Ponka P, Neuwirt J, Sperl M, Brezik Z. The ability of exogenous heme to restore globin

synthesis in reticulocytes with impaired heme formation. Biochem Biophys Res Commun 38: 817-824, 1970.

9. Ponka P, Neuwirt J. Regulation of iron entry into reticulocytes. II. Relationship between

hemoglobin synthesis and entry of iron into reticulocytes. Biochim Biophys Acta 230: 381-392, 1971.

*10. Ponka P, Neuwirt J. Iron uptake by reticulocytes with various rates of heme and globin

synthesis. In: The Regulation of Erythropoiesis and Haemoglobin Synthesis (eds. Travnicek T, Neuwirt J) pp. 326-335. Charles' University, Prague, 1971.

*11. Neuwirt J, Ponka P, Borova J. Regulation of heme synthesis in erythroid cells. In: The

Regulation of Erythropoiesis and Haemoglobin Synthesis (eds. Travnicek T, Neuwirt J) pp. 357-366. Charles' University, Prague, 1971.

12. Neuwirt J, Ponka P, Borova J. Evidence for the presence of free and protein-bound non-

hemoglobin heme in rabbit reticulocytes. Biochim Biophys Acta 264: 235-244, 1972. *13. Neuwirt J, Ponka P, Borova J. The regulation of heme synthesis in erythroid cells. Acta

Univ Palackian Olomuc 64: 225, 1972.

Prem Ponka Publications (continued)

10

*14. Neuwirt J, Ponka P. The regulation of heme synthesis in erythroid cells by the feedback

inhibition of cellular uptake of substrates. In: Synthesis, Structure and Function of Hemoglobin (eds. Martin H, Nowicki L) pp. 61-66. J.F. Lehmanns, Verlag, Munchen, 1972.

15. Ponka P, Neuwirt J. The effect of plasma and transferrin on the hemin inhibition of iron

uptake by reticulocytes. Experientia 28: 189-190, 1972. 16. Borova J, Ponka P, Neuwirt J. Study of intracellular iron distribution in rabbit

reticulocytes with normal and inhibited heme synthesis. Biochim Biophys Acta 320: 143-156, 1973.

17. Ponka P, Borova J, Neuwirt J. Accumulation of heme in mitochondria from rabbit

reticulocytes with inhibited globin synthesis. Biochim Biophys Acta 304: 715-718, 1973. 18. Ponka P, Neuwirt J, Borova J. The use of exogenous δ-aminolevulinic acid for the studies

of the regulation of heme synthesis in rabbit reticulocytes. Biochim Biophys Acta 304: 123-131, 1973.

19. Neuwirt J, Ponka P, Borova J. Heme and production of δ-aminolevulinic acid in rabbit

reticulocytes. Enzyme 17: 100-107, 1974. *20. Neuwirt J, Ponka P. Regulation of hemoglobin synthesis. Babak's Series 62, Avicenum,

Prague, 1974. 21. Ponka P, Neuwirt J, Borova J. The role of heme in the release of iron from transferrin in

reticulocytes. Enzyme 17: 91-99, 1974. 22. Ponka P, Neuwirt J. Heme synthesis and iron uptake by reticulocytes. Brit J. Haematol

28: 1-5, 1974. *23. Neuwirt J, Borova J, Ponka P. Intracellular iron kinetics in erythroid cells. In: Proteins of

Iron Storage and Transport in Biochemistry and Medicine (ed. Crichton RR) pp. 161-166. North Holland Publishing Co., Amsterdam, 1975.

*24. Neuwirt J, Ponka P, Borova J. The regulatory role of heme in erythroid cells. In:

Erythropoiesis. Proceedings of the Fourth International Conference on Erythropoiesis (eds. Nakao K, Fisher JW, Takaku F) pp. 413-421. University of Tokyo Press, 1975.

*25. Ponka P, Neuwirt J. Regulation of iron delivery from transferrin to reticulocytes. In:

Proteins of Iron Storage and Transport in Biochemistry and Medicine (ed. Crichton RR) pp. 147-154. North Holland Publishing Co., Amsterdam, 1975.

26. Ponka P, Neuwirt J. Mitochondrial iron overload. N Engl J Med 293: 406, 1975.


11

*27. Ponka P, Neuwirt J, Borova J. The role of heme in the release of iron from transferrin in

rabbit reticulocytes. In: Erythropoiesis (eds. Nakao K, Fisher JW, Takaku F) pp. 403-411. University of Tokyo Press, 1975.

28. Borova J, Fuchs O, Ponka P, Neuwirt J. A simple liver cell-free system suitable for

testing messenger RNA. Collection Czechoslov Chem Commun 41: 2448-2454, 1976. 29. Fuchs O, Borova J, Ponka P, Neuwirt J. Methods for isolation and detection of globin

mRNA. Biochem Clin Bohemoslov 7: 161-173, 1976. 30. Necas E, Ponka P, Neuwirt J. Study on the proliferative state of haemopoietic stem cells

(CFU). Cell Tissue Kinet 9: 223, 1976. *31. Neuwirt J, Ponka P, Borova J. The non-hemoglobin heme in cytoplasm and mitochondria

of rabbit reticulocytes. In: Abhandlungen der Akademie der Wissenschaften der DDR, pp. 581-586, 1976.

*32. Neuwirt J, Ponka P. Pathophysiology for medical students. Charles' University, Prague,

1976. *33. Neuwirt J, Ponka P. Regulation of hemoglobin synthesis (monograph). Martinus Nijhoff,

The Hague, 1977. 34. Ponka P. Differentiation of erythroid cells. Cs Fysiol 26: 127-146, 1977. 35. Ponka P, Cinatl J. Modern methods for the investigation of hemopoietic stem cells. Cas

Lek Ces 116: 109-113, 1977. 36. Ponka P, Cinatl J. Modern methods for the investigation of hemopoietic stem cells.

Clinical applications. Cas Lek Ces 116: 114-117, 1977. 37. Ponka P, Fuchs O, Borova J, Neuwirt J, Necas E. The onset of hemoglobin synthesis in

spleens of irradiated mice after bone marrow transplantation. Acta Biol Med Germ 36: 353-362, 1977.

*38. Ponka P, Neuwirt J, Borova J, Fuchs O. Control of iron delivery to hemoglobin in

erythroid cells. In: Iron Metabolism. Ciba Foundation Symposium 51 (new series) pp. 167-200. Elsevier/Excerpta Medical/North-Holland and Elsevier, Amsterdam, 1977.

*39. Ponka P, Neuwirt J, Borova J, Fuchs O. The role of mitochondria in the control of iron

delivery to hemoglobin molecules. In: Proteins of Iron Metabolism (eds. Brown EB, Aisen P, Fielding J, Crichton RR) pp. 319-326. Grune and Stratton, New York, 1977.

40. Borova J, Fuchs O, Ponka, P, Neuwirt J. Translation of exogenous mRNA in a wheat

embryo cell-free system. Effect of composition of cell-free system. Collection Czechoslov Chem Commun 43: 900-906, 1978.


12

41. Fuchs O, Borova J, Ponka P, Neuwirt J. Isolation of globin mRNA from spleens of anaemic rabbits and its translation in a wheat embryo cell-free system. Collection Czechoslov Chem Commun 43: 1184-1189, 1978.

42. Necas E, Ponka P, Neuwirt J. Changes in stem cell compartments in mice after

hydroxyurea. Cell Tissue Kinet 11: 119-127, 1978. 43. Necas E, Ponka P, Neuwirt J. Disappearance of hemopoietic stem cells from blood after

hydroxyurea. Folia Biologica (Praha) 24: 78-80, 1978. 44. Ponka P, Cinatl J, Neuwirt J, Necas E. A contribution to the technique of mouse bone

marrow cell culture in semisolid agar. Folia Biologica 24: 68-77, 1978. 45. Necas E, Ponka P, Neuwirt J. Effect of some cytostatics on the haemopoietic stem cells

(CFUs) in blood. Cancer Chemother Pharmacol 2: 215-219, 1979. 46. Necas E, Ponka P, Neuwirt J. Estimation of the pluripotential stem cells in bone marrow

after hydroxyurea. Haematol Bluttransfus 24: 83-86, 1979. 47. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes.

Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97: 317-321, 1979.

48. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron

metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586: 278-297, 1979.

49. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P. Effective iron chelation following

oral administration of isoniazid-pyridoxal hydrazone. Brit J Haematol 43: 443-449, 1979. 50. Hradilek A, Ponka P. Friend leukemia as a model of erythroid differentiation. Cs Fysiol

28: 333-358, 1979. 51. Cirkt M, Ponka P, Neuwirt J, Necas E. Biliary iron excretion in rats following pyridoxal

isonicotinoyl hydrazone. Brit J Haematol 45: 275-283, 1980. 52. Cinatl J, Ponka P, Dobry E, Neuwirt J, Chudomel V, Necas E, Benesova V. Culture of

GM-CFC mouse bone marrow in semisolid agar. Cs Fysiol 29: 33-38, 1980. 53. Ponka P, Borova J, Neuwirt J. Iron and transferrin distribution in reticulocytes incubated

with heme synthesis inhibitors. Biochim Biophys Acta 632: 527-537, 1980. 54. Fuchs O, Ponka P, Borova J, Neuwirt J, Travnicek M. Effect of heme on globin

messenger RNA synthesis in spleen erythroid cells. J Supramol Struct Cell Biochem 15: 73-81, 1981.


13

*55. Ponka P, Wilczynska A. Iron chelating potential of pyridoxal isonicotinoyl hydrazone and structurally related compounds. In: Development of Iron Chelators for Clinical Use (eds. Martell AE, Anderson WF, Badman DG) pp. 287-292. Elsevier/North-Holland, 1981.

56. Schulman HM, Wilczynska A, Ponka P. Transferrin and iron uptake by human

lymphoblastoid and K-562 cells. Biochem Biophys Res Commun 100: 1523-1530, 1981. 57. Schulman HM, Ponka P. The stimulation of globin synthesis by cobalt in reticulocytes

with inhibited heme synthesis. Biochim Biophys Acta 654: 166-168, 1981. 58. Necas E, Ponka P, Neuwirt J. Decreased sensitivity to hydroxyurea and to (3H)thymidine

suicide in the middle of the S-phase. Cell Tissue Kinet 14: 261-267, 1981. 59. Ponka P, Wilczynska A, Schulman HM. Iron utilization in rabbit reticulocytes. A study

using succinylacetone as an inhibitor of heme synthesis. Biochim Biophys Acta 720: 96-105, 1982.

60. Ponka P, Schulman HM, Wilczynska A. Ferric pyridoxal isonicotinoyl hydrazone can

provide iron for heme synthesis in reticulocytes. Biochim Biophys Acta 718: 151-156, 1982.

*61. Ponka P, Wilczynska A. Factors affecting the mobilization of iron from reticulocytes by

isonicotinoyl hydrazones of pyridoxal or pyridoxal phosphate. In: The Biochemistry and Physiology of Iron (eds. Saltman P, Hegenauer J) pp. 275-277, Elsevier, 1982.

*62. Ponka P, Schulman HM, Wilczynska A. Evidence that ferritin iron is not utilized for

heme synthesis in reticulocytes. In: The Biochemistry and Physiology of Iron (eds. Saltman P, Hegenauer J) pp. 493-496, 1982.

63. Huang A, Ponka P. Mechanism of action of pyridoxal isonicotinoyl hydrazone in

reticulocytes incubated in vitro. Biochim Biophys Acta 757: 306-315, 1983. *64. Schulman HM, Wilczynska A, Ponka P. Intracellular transferrin and transferrin receptors

in reticulocytes. In: Structure and Function of Iron Storage and Transport Proteins (eds. Urushizaki I, et al) pp. 305-310. Elsevier, 1983.

65. Wilczynska A, Ponka P, Schulman HM. Transferrin receptors and iron utilization in

DMSO inducible and non-inducible Friend erythroleukemia cells. Exp Cell Res 154: 561-566, 1984.

66. Ponka P, Grady RW, Wilczynska A, Schulman HM. The effect of various chelating

agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta 802: 477-489, 1984.

67. Ponka P, Schulman HM. Regulation of heme synthesis in erythroid cells: Hemin inhibits

transferrin iron utilization but not protoporphyrin synthesis. Blood 65: 850-857, 1985.


14

68. Ponka P, Schulman HM. Acquisition of iron from transferrin regulates reticulocyte heme

synthesis. J Biol Chem 260: 14717-14721, 1985. *69. Ponka P, Schulman HM. Regulation of heme synthesis in erythroid cells by iron delivery

from transferrin. In: Porphyrins and Porphyrias (ed. Nordmann Y) Colloque INSERM/John Libbey Eurotex Ltd., Vol. 134, pp. 56-67, 1986.

70. Laskey JD, Ponka P, Schulman HM. Control of heme synthesis during Freind cell

differentiation: Role of iron and transferrin. J Cell Physiol 129: 185-192, 1986. 71. Schmidt JA, Marshall J, Hayman MJ, Ponka P, Beug H. Control of erythroid

differentiation: Possible role of the transferrin cycle. Cell 46: 41-51, 1986. *72. Richardson D, Baker E, Ponka P, Wilairat P, Vitolo ML, Webb J. Effect of pyridoxal

isonicotinoyl hydrazone and analogues on iron metabolism in hepatocytes and macrophages in culture. In: Thalassemia: Pathophysiology and Management. Birth Defects: Original Article Series, Volume 23, Number 5B, pp. 81-88, 1988.

73. Ponka P, Schulman HM, Martinez-Medellin J. Heme inhibits iron uptake subsequent to

endocytosis of transferrin in reticulocytes. Biochem J 251: 105-109, 1988. 74. Laskey J, Webb I, Schulman HM, Ponka P. Evidence that transferrin supports cell

proliferation by supplying iron for DNA synthesis. Exp Cell Res 176: 87-95, 1988. 75. Ponka P, Richardson D, Baker E, Schulman HM, Edward JT. Effect of pyridoxal

isonicotinoyl hydrazone (PIH) and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 967: 122-129, 1988.

76. Edward JT, Gauthier M, Chubb FL, Ponka P. Synthesis of new acylhydrazones as iron chelating compounds. J Chem Eng Data 33: 538-540, 1988. 77. Schulman HM, Ponka P, Wilczynska A, Gauthier Y, Shyamala G. Transferrin receptor

and ferritin levels during mammary gland development. Biochim Biophys Acta 1010: 1-6, 1989.

*78. Ponka P, Schulman HM. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogues: A

new group of effective chelators. In: Trace Elements in Man and Animals VI (eds. Hurley LS, et al), Plenum Publishing Corp., pp. 61-65, 1989.

*79. Ponka P, Schulman HM, Cox T. Iron metabolism in relation to heme synthesis. In:

Biosynthesis of Heme and Chlorophylls, (ed. Dailey HA), McGraw-Hill Publishing Co., pp. 393-434, 1990.

*80. Cox TM, Ponka P, Schulman HM. Erythroid cell iron metabolism and heme synthesis.

In: Iron Transport and Storage (eds. Ponka P, Schulman HM, Woodworth RC) CRC Press, Inc., pp. 263-279, 1990.


15

*81. Kühn L, Schulman HM, Ponka P. Iron-transferrin requirements and transferrin receptor expression in proliferating cells. In: Iron Transport and Storage (eds. Ponka P, Schulman HM, Woodworth RC) CRC Press, Inc., pp. 149-191, 1990.

82. Garrick LM, Hoke JE, Gniecko K, Al-Nakeeb A, Ponka P, Garrick MJ. Ferric-

salicylaldehyde isonicotinoyl hydrazone, a synthetic iron chelator, alleviates defective iron utilization by reticulocytes of the Belgrade rat. J Cell Physiol 146: 460-465, 1991.

83. Baker E, Richardson D, Gross S, Ponka P. Effect of hydrazones of pyridoxal,

salicylaldehyde and 2-hydroxy-1-naphtylaldehyde on iron metabolism in hepatocytes in culture. Hepatology 15: 492-501, 1992.

84. Chan RYY, Ponka P, Schulman HM. Transferrin-receptor independent iron-dependent

proliferation in variant Chinese hamster ovary cells. Exp Cell Res 202: 326-336, 1992. 85. Chan RYY, Schulman HM, Ponka P. The expression of ferrochelatase mRNA in

erythroid and nonerythroid cells. Biochem J 292: 343-349, 1993. 86. Ponka P, Schulman HM. Regulation of heme biosynthesis: Distinct regulatory features

in erythroid cells. Stem Cells 11, Suppl. 1: 24-35, 1993. 87. Chan RYY, Schulman HM, Ponka P. Regulation of transferrin receptor mRNA

expression: Distinct regulatory features in erythroid cells. Eur J Biochem 220: 683-692, 1994.

*88. Ponka P. Physiology and pathophysiology of iron metabolism: Implications for iron

chelation therapy in iron overload. In: The Development of Iron Chelators for Clinical Use (eds. Bergeron R, Brittenham G) CRC Press, Inc., pp. 1-32, 1994.

*89. Ponka P, Schulman HM. Distinct features of iron metabolism in erythroid cells:

Implications for heme synthesis regulation. In: Progress in Iron Research (eds. Hershko C, Konijhn AN, Aisen P) Plenum Publishing Corp., pp. 173-187, 1994.

90. Richardson DR, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine,

on iron and transferrin uptake by the human malignant melanoma cells. Cancer Res 54: 685-689, 1994.

91. Ponka P, Richardson DR, Edward JT, Chubb JL. Iron chelators of the pyridoxal

isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro. Can J Physiol Pharmacol 72: 659-666, 1994.

92. Hermes-Lima M, Wang EM, Schulman HM, Storey KB, Ponka P. Deoxyribose

degradation by Fe(III)-EDTA: kinetic aspects and potential usefulness for sub-micromolar iron measurements. Mol Cell Biochem 137: 65-73, 1994.


16

93. Alcantra O, Obeid L, Hannum Y, Ponka P, Boldt DH. Regulation of protein kinase C expression by iron: Effect of different iron compounds on PKC-ß and PKCα- gene expression and role of the 5'-flanking region of the PKC-ß gene in the response to diferric transferrin. Blood 84: 3510-3517, 1994.

94. Richardson DR, Ponka P. The iron metabolism in the human neuroblastoma cells.

Relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124: 660-671, 1994.

95. Richardson DR, Neumannova V, Ponka P. Nitrogen monoxide decreases iron uptake

from transferrin but does not mobilise iron from prelabelled neoplastic cells. Biochim Biophys Acta 1266: 250-260, 1995.

96. Edward JT, Ponka P, Richardson DR. Partition coefficients of the iron(III) complexes of

pyridoxal isonicotinoyl hydrazone and its analogues and the correlation to iron chelation efficacy. BioMetals 8: 209-217, 1995.

97. Schulman HM, Hermes-Lima M, Wang E-M, Ponka P. In vitro antioxidant properties of

the iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and some of its analogs. Redox Report 1: 373-378, 1995.

98. Kennard ML, Richardson DR, Gabathuler T, Ponka P, Jefferies WA. A novel iron uptake

mechanism mediated by GP-1-anchored human melanotransferrin. EMBO J 14: 4178-4186, 1995.

*99. Nestel F, You-Ten KE, Kichian K, Desbarats J, Price K, Ponka P, Seemayer TA, Lapp

WS. The role of endotoxin in the pathogenesis of graft-vs-host disease. In: Graft-vs-Host Disease (eds. Burakoff SJ, Deeg HJ, Ferrar J, Atkinson L) Dekker, N.Y., pp. 501-523, 1996.

100. Richardson DR, Ponka P. Identification of a mechanism of iron uptake by cells which is

stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim Biophys Acta 1269: 105-114, 1995.

101. Richardson DR, Neumannova V, Nagy E, Ponka P. The effect of redox-related species of

nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Blood 86: 3211-3219, 1995.

102. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of pyridoxal

isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood 86: 4295-4306, 1995.

103. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition

of heme synthesis with succinylacetone. Examination of cytoplasmic and mitochondrial intermediates involved in iron metabolism. Blood 87: 3477-3488, 1996.

*104. Richardson DR, Ponka P. Effects of nitrogen monoxide on cellular iron metabolism.

Methods in Neurosciences, Vol. 31 (ed. Maines MD), pp. 329-345, 1996.


17

105. Loyevsky M, Tsafack A, Ponka P, Cabantchik ZI. Mode of action of iron(III) chelators as

antimalarials. IV. Potentiation of Desferal action by benzoyl- and isonicotinoyl-hydrazone derivatives. J Lab Clin Med 127: 574-582, 1996.

106. Fuchs O, Ponka P. The role of iron supply in the regulation of 5-amino-levulinate

synthase mRNA levels in murine erythroleukemia cells. Neoplasma 43: 31-36, 1996. 107. Bonkovsky HL, Ponka P, Bacon BR, Drysdale J, Grace NC, Tavill AS. An update on

iron metabolism: Summary of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism. Hepatology 24: 718-729, 1996.

108. Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS. In vivo evidence for interleukin-12

mediated interferon- production in target organs during acute graft-versus-host disease. J Immunol 157: 2851-2856, 1996.

109. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331: 1-40, 1997. 110. Bhattacharya M, Ponka P, Hardy P, Varma D, Lachapelle P, Chemtob S. Prevention of

post-asphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Rad Biol Med 22: 11-16, 1997.

111. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: Distinct

control mechanisms in erythroid cells (Invited Review; peer reviewed). Blood 89: 1-25, 1997.

112. Ponka P, Richardson DR. Can ferritin provide iron for hemoglobin synthesis? Blood 89:

2611-2612, 1997. 113. Golenser J, Domb A, Teomin D, Tsafack A, Nisim O, Ponka P, Cabantchik ZI. The

treatment of animal models of malaria with iron chelators by use of novel polymeric device for slow drug release. J Pharmacol Exp Therapeut 281: 1127-1135, 1997.

114. Lee R, Beauparlant P, Elford H, Ponka P, Hiscott J. Selective inhibition of IκB

phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology 234, 277-290, 1997.

115. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin

(Invited Review; peer reviewed). Seminars in Hematology 35: 35-54, 1998. 116. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues: Potential

orally effective iron chelating agents for the treatment of iron overload disease. J Lab Clin Med 131: 306-314, 1998.

117. Blaha K, Cikrt M, Nerudova J, Fornuskova H, Ponka P. Biliary iron excretion in rats

following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 91: 4368-4372, 1998.


18

118. Richardson DR, Ponka P. The development of iron chelators to treat iron overload

disease and their use as experimental tools to probe intracellular iron metabolism. Amer J Hematol 58: 299-305, 1998.

119. Hermes-Lima M, Nagy E, Schulman HM, Ponka P. The iron chelator pyridoxal

isonicotinoyl hydrazone (PIH) and analogs protect plasmid pUC-18 DNA against strand breaks induced by •OH radicals. Free Rad Biol Med 25: 875-880, 1998.

120. Necas E, Ponka P. Ureter obliteration transiently depresses erythropoietin production in

the affected kidney of the mouse. Europ J Clin Invest 28: 918-921, 1998. 121. Richardson DR, Ponka P. Orally effective iron chelators for the treatment of iron

overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs (Invited Review; peer reviewed). J Lab Clin Med 132: 351-352, 1998.

122. Ponka P. Cellular iron metabolism (Invited Review; peer reviewed). Kidney International

55, Suppl.69: S2-S11, 1999. 123. Hermes-Lima M, Santos NCF, Yan J, Andrews M, Schulman HM, Ponka P. EPR spin

trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on •OH formation by Fenton reaction. Biochim Biophys Acta 1426: 475-482, 1999.

124. Ponka P, Lok CN. Transferrin receptor: Role in health and disease (Invited Review; peer

reviewed). Internat J Biochem Cell Biol 31: 1111-1117, 1999. 125. Lok CN, Ponka P. Identification of hypoxia response element in the transferrin receptor

gene. J Biol Chem 274: 24147-24152, 1999. 126. Canonne-Hergaux F, Gruenheid S, Ponka P, Gros P. Cellular and subcellular localization

of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 93: 4406-4417, 1999.

127. Ponka P. Cell biology of heme (Invited Review; peer reviewed). Am J Med Sci 318: 241-

256, 1999. 128. Kim S, Ponka P. Control of transferrin receptor expression via nitric oxide-mediated

modulation of iron-regulatory protein-2. J Biol Chem 274: 33035-33042, 1999. *129. Necas E, Sulc K, Zivny JH, Sykora V, Ponka P. Red blood cell degradation products

modify responsiveness of erythropoietin gene to hypoxia. In: Advances in Experimental Biology and Medicine (eds. Eke A, Delpy DT) Plenum Publ., Vol. 471, pp. 427-437, 1999.

130. Ponka P. Iron metabolism: Physiology and Pathophysiology. J Trace Elem Exp Med 13:

73-83, 2000.


19

131. Nestel FP, Kichian K, Greene RN, Ponka P, Lapp WS. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: Release of intracellular iron and nitric oxide-mediated cytostasis. Blood 96: 1836-1843, 2000.

132. Ponka P, Zhang A-S, Lok CN. Metabolism and transport of iron: Distinct control

mechanism in erythroid cells. In: Iron Chelators: New Development Strategies (eds. Badman DG, Bergeron R, Brittenham G), Saratoga Publ. Group, Ponte Vedra, FL, pp. 115-132, 2000.

133. Kim S, Ponka P. Effects of interferon- and lipopolysaccharide on macrophage iron

metabolism are mediated by nitric oxide-induced degradation of iron regulator protein 2. J Biol Chem 275: 6220-6226, 2000.

134. Lok CN, Ponka P. Identification of an erythroid-active element in the transferrin receptor

gene. J Biol Chem 275: 24185-24190, 2000. 135. Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator

salicylaldehyde isonicotinoyl hydrazone (SIH) in the prevention of H2O2 injury in adult cardiomyocytes. Cardiovasc Res 47: 529-536, 2000.

136. Hermes-Lima M, Ponka P, Schulman HM. The iron chelator pyridoxal isonicotinoyl

hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim Biophys Acta 1523: 154-160, 2000.

*137. Ponka P. Iron deficiency. In: Conn’s Current Therapy (eds. Rakel RE, Bope ET) W.B.

Saunders, 2001, pp 369-376, 2001. 138. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron

chelators for the treatment of Friedreich’s ataxia: Ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536: 133-140, 2001.

*139. Ponka P. Transferrin receptor (CD71). In: Encyclopedia of Molecular Medicine, Vol. 5

(ed. Creighton T), John Wiley & Sons, pp.3211-3216, 2001. 140. Canonne-Hergaux F, Zhang A.S, Ponka P, Gros P. Characterization of iron transporter

DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. Blood 98: 3823-3830, 2001.

*141. Ponka P. Iron utilization in erythrocyte formation and hemoglobin synthesis. In: Molecuar and Cellular Iron Transport (ed. Templeton DM), Marcel Dekker, pp.643-677, 2002. 142. Becker EM, Greer JM, Ponka P, Richardson DR. Erythroid differentiation

andprotoporphyrin IX down-regulate frataxin expression in Friend cells: Characterization of Frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood 99: 3813-3822, 2002.


20

143. Lobmayr L, Sauer T, Killisch I, Schranzhofer M, Wilson RB, Ponka P, Beug H, Müllner EW. Transferrin recptor hyperexpression in primary erythroblasts is lost upon transformation by avian erythroblastosis virus. Blood 100: 289-298, 2002.

144. Ponka P, Kim S. S-Nitrosothiols control breathing and oxygen homeostasis. Redox

Report 7: 5-7, 2002. 145. Buss JL, Hermes-Lima M, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues.

Adv Exp Med Biol 509: 205-229, 2002. 146. Ponka P, Sheftel AD, Zhang A.S. Iron targeting to mitochondria in erythroid cells.

Biochem Soc Trans 30: 735-738, 2002. 147. Buss JL, Neuzil J, Ponka P. The role of oxidative stress in the toxicity of pyridoxal

isonicotinoyl hydrazone (PIH) analogues. Biochem Soc Trans 30: 755-757, 2002. 148. Kim S, Ponka P. Nitrogen monoxide-mediated control of ferritin synthesis: Implications

for macrophage iron homeostasis. Proc Natl Acad Sci USA 99: 12214-12219, 2002.

149. Wang J, Buss J, Chen G, Ponka P, Pantopoulos K. The prolyl-4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS Lett 529: 309-312, 2002.

150. Ponka P. Rare causes of hereditary iron overload. Semin Hematol (Invited Review; peer

reviewed) 39: 249-262, 2002. 151. Buss JL, Arduini E, Ponka P. Mobilization of intracellular iron by analogs of pyridoxal

isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the Fe-chelator complex. Biochem Pharmacol 64: 1689-1701, 2002.

152. Adamcova M, Machackova J, Gersl V, Pelouch V, Simunek T, Klimtova I, Hrdina R,

Ponka P. Cardiac troponin T following repeated administration of pyridoxal isonicotinoyl hydrazone in rabbits. Physiol Res 51: 443-448, 2002.

153. Kim S, Ponka P. Nitric oxide-mediated modulation of iron regulatory proteins:

Implications for cellular iron homeostasis. Blood Cells, Molecules and Diseases 29: 400-410, 2002.

154. Buss JL, Neuzil J, Gellert N, Weber C, Ponka P. Pyridoxal isonicotinoyl hydrazone

analogs induce apoptosis in hematopoietic cells due to their iron chelating properties. Biochem Pharmacol 65: 161-172, 2003.

155. Buss JL, Arduini E, Shephard KC, Ponka P. Lipophilicity of analogs of pyridoxal

isonicotinoyl hydrazone (PIH) predicts efflux of Fe complexes, which determines their chelating efficiency and toxicity toward K562 cells. Biochem Pharmacol 65: 349-360, 2003.


21

156. Kim S, Ponka P. Role of nitric oxide in cellular iron metabolism. Biometals 16: 125-135, 2003.

157. Buss JL, Ponka P. Hydrolysis of pyridoxal isonicotinoyl hydrazone (PIH) and its analogs.

Biochim Biophys Acta 1619: 177-186, 2003. 158. Watts RN, Ponka P, Richardson DR. Effects of nitrogen monoxide and carbon monoxide

on molecular and cellular iron metabolism: Mirror-image effector molecules that target iron. Biochem J 369: 429-440, 2003.

159. Link G, Ponka P, Kohijn AM, Breuer W, Cabantchik ZI, Hershko C. Effects of combined

chelation treatment with pyridoxal isonicotinoyl hydrazone (PIH) analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101: 4172-4179, 2003.

160. Ponka P. Recent advances in cellular iron metabolism. J Trace Elem Exp Med 16: 1-17,

2003. 161. Buss JL, Neuzil J, Ponka P. Oxidative stress mediated toxicity of pyridoxal isonicotinoyl

hydrazone analogs. Arch Biochem Biophys 421: 1-9, 2004. 162. Kim S, Wing S, Ponka P. S-nitrosylation of IRP2 regulates its stability via the ubiquitin-

proteasome pathway. Mol Cell Biol 24:330-337, 2004. 163. Koury MJ, Ponka P. New insights into erythropoiesis: The roles of folate, vitamin B12

and iron. Annu Rev Nutr 24: 105-131, 2004. 164. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system.

Ann N Y Acad Sci (Invited Review; peer reviewed) 1012: 267-281, 2004. 165. Priwitzerova M, Pospisilova D, Prchal JT, Indrak K, Hlobilkova A, Mihal V, Ponka P*,

Divorky V. Severe hypochromic microcytic anemia caused by a congenital defect of iron transport pathway in erythroid cells. Blood 103: 3991-3992, 2004. *Corresponding author.

166. Crowe WE, Maglova LM, Ponka P, Russell JM. Human cytomegalovirus induced host

cell enlargement is iron dependent. Am J Physiol Cell Physiol 287: C1023-C1030, 2004. 167. Zhang A-S, Sheftel AD, Ponka P. Intracellular kinetics of iron in reticulocytes: evidence

for endosome involvement in iron targeting to mitochondria. Blood 105: 368-375, 2005. 168. Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, Divoky V, Prchal

JT. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105: 1337-1342, 2005. 169. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R,

Gersl V, Ponka P. Study of Daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 51: 223-231, 2005.


22

170. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: Novel

pathways revealed by disease. Blood 105: 1867-1874, 2005. 171. Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes

cytosolic iron starvation and changes cellular iron homeostasis. This article was accompanied by Editorial Commentary by Chitambar CR: Cellular iron metabolism; Mitochondria in the spotlight. Blood 105, 1844-1845, 2005.

172. Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW,

Koromilas AE, Pantopoulos K. Iron inactivites the RNA polymerase N25B and suppresses subgenomic replication of hepatitis C virus. J Biol Chem 280: 9049-9057, 2005.

173. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Streba M, Gersl V,

Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 39: 345-354, 2005.

174. Priwitzerova M, Nie G, Sheftel AD, Pospisilova D, Divoky V, Ponka P. Functional

consequences of the human DMT1 (SLC11A2) mutation on protein expression and iron uptake. Blood 106: 3985-3987, 2005.

175. Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P.

Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 28: 1300-1306, 2005.

176. Sterba M, Popelova O, Mazurova Y, Adamcova M, Gersl V, Ponka P. Safety and

tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Human and Experimental Toxicology 24: 581-589, 2005.

177. Mouralian C, Buss JL, Stranix B, Chin J, Ponka P. Mobilization of iron from cells by

hydroxyquinoline-based chelators. Biochem. Pharmacol 71: 214-222, 2005.

*178. Ponka P. Genetically-based iron deficient erythropoiesis. HEMATOLOGY eDIGEST Newsletter (The Johns Hopkins University School of Medicine), Volume 1, Issue 8, April

2006 (http://www.hopkinscme.net/ofp/hematologyedigest/newsletter/pdf_042806.pdf). 179. Zhang AS, Sheftel AD, Ponka P. The anemia of “haemoglobin deficit” (hbd/hbd) mice is

caused by a defect in transferrin cycling. Exp Hematol 34: 593- 598, 2006. 180. Watts RN, Hawkins C, Ponka P*, Richardson DR. Nitrogen monoxide (NO)-mediated

iron release from cells is linked to NO-induced glutatione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci USA 103: 7670-7675, 2006. *Corresponding author.


23

181. Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, Ponka P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 838: 107-112, 2006.

182. Mikhael M. Kim SF, Schranzhofer M, Shan SI, Sheftel AD, Mullner E, Ponka P. Iron

regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide. FEBS J 273: 3828-3836, 2006.

183. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P. Semenza,

GL, Schumacher A, Prchal JT. Schumacher A, Prchal JT. HIF-1 alpha-deficiency results in dysregulated EPO signaling and iron homeostasis in mouse development. J Biol Chem.

281: 25703-25711, 2006. 184. Whitnall M, Howard J, Ponka P*, Richardson DR. A novel class of iron chelators with a

wide spectrum of potent anti-tumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103: 14901-14906, 2006. *Corresponding author.

185. Sterba M, Popelova O, Simunek T, Marzurova Y, Potacova A, Adamcova M, Kaiserova

H, Ponka P, Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorbenzoyl hydrazone, in the rabbit model of daunorubicin-indcued cardiotoxicity. J Pharm and Exp Therap 319: 1336-1347, 2006.

186. Nie G, Chen G, Sheftel AD, Pantopoulos K, Ponka P. Effects of mitchondrial ferritin expression on tumor iron metabolism and on tumor growth in nude mice xenografts. Blood 108: 2428-2434, 2006. This article was accompanied by Editorial

Commentary by Richardson DR, Lovejoy DR. Iron mining to inhibit tumor growth. Blood 108: 2140, 2006.

*187. Ponka P, Tenenbein M, Eaton J. Iron. In: Handbook of Toxicology of Metals, Third Ed. (G Nordberg, B Fowler, M Nordberg, L Fridberg, eds.), Elsevier pp 577-598, 2007.

188. Sheftel AD, Kim SF, Ponka P. Non-heme induction of heme oxygenase-1 does not alter cellular iron metabolism. J Biol Chem 282: 10480-10486, 2007.

189. Sheftel AD, Zhang AS, Brown C, Shirihai OS, Ponka P. Direct interorganellar transfer

of iron from endosome to mitochondrion. Blood 110: 125-132, 2007. 190. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I,

Kaiserova H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology 235: 150-166, 2007.

191. Potacova A, Adamcova M, Cajnakova H, Hrbatova L, Sterba M, Popelova O, Simunek T,

Ponka G, Gersl V. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. Physiol Res 56: 251-251, 2007.


24

192. Simunek T, Sterba M, Popelova O, Kaiserova H, Potacova A, Adamcova M, Mazurova

Y, Ponka P, Gersl V. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity. Hemoglobin 32: 207-215, 2008.

193. Szuber N, Buss JL, Soe-Lin S, Felfy H, Trudel M, Ponka P. Alternative treatment

paradigm for thalassemia using iron chelators. Exp Hematol 36: 773-785, 2008. 194. Soe-Lin S, Sheftel AD, Wasyluk B, Ponka P. Nramp1 equips macrophages for efficient

iron recycling. Exp Hematol 36: 929-937, 2008.

195. Zhang A-S, Canonne-Hergaux F, Gruenheid S, Gros P, Ponka P. The use of Nramp-2-transfected Chinese hamster ovary cells and reticulocytes from mk/mk mice to study iron transport mechanisms. (Exp Hematol, in press).

196. Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, Ponka P, Gersl

V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. (Brit J Pharmacol, in press).

197. Whitnall M. Suryo Rahmanto Y, Sutak R, Xu X, Becker EM, Mikhael M, Ponka P*,

Richardson DR. The MCK mouse heart model of Friedreich’s Ataxia: Marked alterations in iron-regulated proteins and iron chelation limits cardiac hypertrophy. Proc Natl Acad Sci USA 105: 9757-9762, 2008. * Corresponding author.

198. Schipper HM, Ponka P. Inherited disorders of brain iron metabolism. In Iron Deficiency

and Overload: From Basic Biology to Clinical Medicine (S Yehuda, D Mostofsky, eds) (in press).

MISCELLANEOUS ARTICLES AND NOTES 1. Ponka P. Perspectives in the therapy of certain hereditary anemias. Vesmir 51: 380, 1972. 2. Ponka P. Reticulocyte - an immature red cell. Vesmir 52: 17-19, 1973. 3. Ponka P. Does cyclic adenosine monophosphate control cell proliferation? Vesmir 52:

253, 1973. 4. Ponka P, Necas E. The history of the discovery of blood groups. Vesmir 52: 344, 1973. 5. Schulman HM, Ponka P. Gallium transferrin binding in Alzheimer disease. Lancet 335:

1348, 1990.

6. Ponka P. Sunlight and porphyria patients. The National Newsletter of the Canadian Porphyria Foundation, pp. 1-2, May 1990 (reprinted in American Porphyria Foundation Newsletter, Fall, 1990, p. 1-2).

Prem Ponka

25

MISCELLANEOUS ARTICLES AND NOTES (continued) 7. Ponka P. AIP. The National Newsletter of the Canadian Porphyria Foundation, pp. 2-4,

November 1990 (reprinted in American Porphyria Foundation Newsletter, Spring 1991, pp. 1-2).

8. Ponka P, Prchal JF, Palek J, Prchal JT Obituary: Jan Neuwirt (1927-1993). Exp Hematol

22: 479, 1994. 9. Ponka P. Nitric oxide (NO): Our friend and foe. In: Lay Medix (eds. Gold P, Shuster J),

Vol. 4, pp. 1-4, 1996. 10. Ponka P. Has the hemochromatosis gene been identified? Internet Publ

(http://home.iSTAR.ca/~chcts/ponmar97.htm). 11. Ponka P. Syndromes of iron overload in humans. Nutrition & the M.D. 25: 1-4, 1999. 12. Ponka P. Abnormal mitochondrial iron metabolism in Friedreich ataxia. Blood Cells Mol

Dis 29:548-549, 2002. 13. Ponka P. Iron and cell proliferation: another piece of the puzzle. Blood 104: 2620-2621,

2004. 14. Ponka P. Iron is still hot: hepcidin keeps it ablaze. Blood 105: 1376-1377, 2005. 15. Ponka P, Sheftel AD. It’s hepcidin again, but is it the only master? Blood 108: 3631-

3632, 2006. 16. Ponka P, Andriopoulos D. Iron can boost hepcidin both ways. Blood 110: 1703-1704,

2007.

Prem Ponka

26

ABSTRACTS 1. Ponka P, Neuwirt J. Feedback effect of heme on its own synthesis and the entry of iron

into red blood cells. FEBS Meeting Abstracts (4th) Oslo, p. 24, No. 94, 1967. 2. Neuwirt J, Borova J, Ponka P. Effect of heme on globin synthesis in reticulocytes from

human cord blood and bled rabbits. FEBS Meeting Abstracts (4th) Oslo, p. 24, 1967. 3. Prchal J, Ponka P, Neuwirt J. The use of 59Fe-labelled hemin to study disturbed synthesis

of hemoglobin. Cs Fysiol 17: 215, 1968. 4. Neuwirt J, Ponka P, Prchal J. The synthesis of heme during inhibited synthesis of globin.

Cs Fysiol 17: 214-315, 1968. 5. Ponka P, Neuwirt J, Prchal J. Relationship between iron entry into reticulocytes and

hemoglobin synthesis. Cs Fysiol 17: 215, 1968. 6. Ponka P, Neuwirt J. The synthesis of heme from intracellular non-heme iron pool. FEBS

Meeting Abstracts (5th) Prague, p. 127, No. 507, 1968. 7. Neuwirt J, Ponka P, Borova J. The effect of heme on the synthesis of delta-

aminolevulinic acid in rabbit reticulocytes and hemolysate. FEBS Meeting Abstracts (5th) Prague, p. 128, No. 509, 1968.

8. Ponka P, Neuwirt J, Necas E. Increase in heme synthesis in reticulocytes after bleeding.

Physiol Bohem 17: 481, 1968. 9. Borova J, Neuwirt J, Ponka P. The effect of various factors on the activity of delta-

aminolevulinic acid synthetase in rabbit reticulocytes. FEBS Meeting Abstracts (6th) Madrid, p. 293, 1969.

10. Ponka P, Neuwirt J. The iron uptake by reticulocytes with inhibited globin synthesis.

FEBS Meeting Abstracts (6th) Madrid, p. 357, 1969. 11. Ponka P, Neuwirt J, Necas E. The effect of erythropoietic stimuli on 59Fe incorporation

into the spleen. Physiol Bohem 18: 481, 1969. 12. Ponka P, Neuwirt J. Utilization of intracellular non-heme iron for heme synthesis.

Physiol Bohem 18: 363, 1969. 13. Neuwirt J, Borova J, Ponka P. Regulation of delta-aminolevulinic acid synthesis in rabbit

reticulocytes. Physiol Bohem 18: 359-360, 1969. 14. Ponka P, Neuwirt J, Stoklasova H. Effect of exogenous delta-aminolevulinic acid (ALA)

on synthesis of heme in reticulocytes. Physiol Bohem 20: 403, 1971. 15. Neuwirt J, Ponka P, Stoklasova H. Regulation of heme synthesis in erythroid cells by

feedback inhibition of cellular uptake of substrates. Physiol Bohem 20: 395, 1971.

Prem Ponka Abstracts (continued)

27

16. Ponka P, Neuwirt J, Stoklasova H, Brezik Z. Regulation of glycine transport into

erythroid cells. Physiol Bohem 21: 107, 1972. 17. Ponka P, Neuwirt J, Borova J. Role of heme in release of iron from transferrin in

reticulocytes. HSZ Physiol 354: 846, 1973. 18. Neuwirt J, Ponka P. Use of exogenous -aminolevulinic acid for studies of regulation of

heme synthesis in rabbit reticulocytes. HSZ Physiol 354: 847, 1973. 19. Necas E, Ponka P, Neuwirt J. Changes in circulating stem-cells induced by some

cytostatics. Exp Hematol 5: 32, 1977. 20. Necas E, Ponka P, Neuwirt J. Pluripotent stem-cells of hematopoiesis (CFCs) in blood.

Effect of hypoxia. Sb Lekar 80: 322-323, 1978. 21. Ponka P, Neuwirt J, Necas E, Borova J. Mobilization of iron from reticulocytes with

inhibited heme synthesis using various chelating agents. Proceedings of the 17th Congress of the International Society of Haematology, Paris, Abstracts 1, p. 276, July 25-29, 1978.

22. Ponka P, Borova J, Neuwirt J, Fuchs O. Intracellular transit iron pool in rabbit

reticulocytes. FEBS Meeting Abstracts (12th), Dresden, p. 94, No. 825, 1978. 23. Fuchs O, Borova J, Ponka P, Neuwirt J, Necas E. The effect of hemin on globin mRNA

synthesis. FEBS Meeting Abstracts (12th) Dresden, p. 118, No. 1112, 1978. 24. Necas E, Ponka P, Neuwirt J. Perturbation of CFUs kinetics after hydroxyurea. Exp

Hematol 7, Suppl. 6: 147, 1979. 25. Ponka P, Fuchs O, Borova J, Neuwirt J. Effect of heme on globin mRNA synthesis in

spleen erythroid cells. J Supramol Struct Suppl 4: 187, 1980. 26. Ponka P, Cikrt M, Neuwirt J. An effective iron chelator: Pyridoxal isonicotinoyl

hydrazone. Fed Proc 39: 894, 1980. 27. Ponka P, Wilczynska A. Iron mobilization from cells and tissues by pyridoxal

isonicotinoyl hydrazone. 18th Congress of the International Society of Hematology, Montreal, Abst. No. 824, August 16-22, 1980.

28. Ponka P, Schulman HM, Wilczynska A. Effect of succinylacetone on hemoglobin

synthesis and iron metabolism in rabbit reticulocytes. 18th Congress of the International Society of Hematology, Montreal, Abst. No. 597, August 16-22, 1980.

29. Ponka P, Schulman HM, Wilczynska A. Control of iron uptake by erythroid and non-

erythroid cells. Can Physiol 11: 113, 1980.


28

30. Ponka P, Schulman HM, Wilczynska A. Mechanism and control of transferrin and iron

uptake by normal and transformed hematopoietic cells. Presented at the International Symposium on Cellular and Molecular Biology of Hematopoietic Stem Cell Differentiation, Honey Harbor, Ontario, September 20-24, 1981.

31. Ponka P, Schulman HM, Wilczynska A. The ability of ferric pyridoxal isonicotinoyl

hydrazone to provide iron for heme synthesis in reticulocytes. Blood 58, Suppl. 1: 332, 1981.

32. Ponka P, Schulman HM, Wilczynska A. Transferrin receptors in reticulocyte cytosol.

Proc Can Fed Biol Soc 25: 162, 1982. 33. Wilczynska A, Schulman HM, Ponka P. Transferrin receptors and iron utilization in

DMSO inducible and non-inducible Friend erythroleukemia cells. Proc Can Fed Biol Soc 25: 163, 1982.

34. Ponka P, Schulman HM, Wilczynska A. Hemin inhibits heme but not protoporphyrin

synthesis in erythroid cells. Blood 60, Suppl. 1: 23a, 1982. 35. Wilczynska A, Ponka P, Schulman HM. Control of transferrin receptor expression and

iron utilization in Friend erythroleukemia cells. Proc. 6th International Conference on Proteins of Iron Storage and Transport, Sapporo, Japan, 1983.

36. Ponka P, Schulman HM. The rate of iron delivery from transferrin limits the rate of heme

synthesis in reticulocytes. Blood 64, Suppl. 1: 41a, 1984. 37. Schulman HM, Wilczynska A, Ponka P. Transferrin dependent phosphorylation of

reticulocyte transferrin receptors. Blood 64, Suppl. 1: 42a, 1984. 38. Pulido G, Ponka P, Schulman HM. Preparation and properties of transferrin to which iron

is bound irreversibly. Proc Can Fed Biol Soc 28: 69, 1985. 39. Laskey J, Ponka P, Schulman HM. The control of heme synthesis in differentiating

Friend erythroleukemia cells. Proc Can Fed Biol Soc 28: 107, 1985. 40. Martinez-Medellin J, Benavides L, Ponka P, Schulman HM. Ironing out a model for the

uptake of transferrin and transferrin-iron by the reticulocyte: Partial characterization of two distinct classes of transferrin receptors with different binding affinities. Proc. 7th International Conference on Proteins of Iron Metabolism, Lille (France), p. 40, June 30-July 5, 1985.

41. Pulido G, Ponka P, Schulman HM. Transferrin-iron complexes from which iron is not

incorporated into heme. Proc. 7th International Conference on Proteins of Iron Metabolism, Lille (France) p. 51, June 30-July 5, 1985.

42. Ponka P, Laskey J, Schulman HM. Evidence that iron uptake from transferrin regulates

hemoglobin synthesis. Proc. 7th International Conference on Proteins of Iron


29

Metabolism, Lille (France) p. 68, June 30-July 5, 1985. 43. Wilairat PP, Ponka P, Vitolo ML, Webb J, Richardson D, Baker E. Effect of analogues of

pyridoxal isonicotinoyl hydrazone on iron exchange with hepatocytes and macrophages. Abstracts of the International Conference on Thalassemia, Bangkok (Thailand) p. 143, June 30-July 3, 1985.

44. Ponka P, Schulman HM. The rate of iron delivery from transferrin limits the rate of heme

synthesis in reticulocytes. Abstracts of the First International Symposium on Iron Transport-Storage-Metabolism, Tubingen (W. Germany) July 10-12, 1985.

45. Ponka P, Gauthier M, Baker E, Schulman HM, Edward J. Mobilization of iron from iron-

loaded cells by pyridoxal isonicotinoyl hydrazone (PIH) and other acyl hydrazones. Blood 66, Suppl. 1: 49a, 1985.

46. Pulido-Cejudo G, Schulman HM, Ponka P. Preparation and biological function of

transferrin-iron complexes from which iron is not released upon acidification. Blood 66, Suppl. 1: 49a, 1985.

47. Laskey JD, Ponka P, Schulman HM. Iron uptake from transferrin regulates hemoglobin

synthesis in differentiating Friend erythroleukemia cells. Blood 66, Suppl. 1: 169a, 1985. 48. Wilczynska A, Shyamala G, Schulman HM, Ponka P. Stimulation of transferrin receptor

levels in murine mammary glands during pregnancy. Proc Can Fed Biol Soc 29: 217, 1986.

49. Baker E, Richardson D, Ponka P. Effect of analogues of pyridoxal isonicotinoyl

hydrazone on iron exchange between hepatocytes and transferrin. Abstracts of the 21st Congress of the International Society of Hematology, Sydney (Australia), Abst. No. P-TU-132B-5, May 11-16, 1986.

50. Ponka P, Schulman HM. Mechanism by which heme inhibits iron uptake from transferrin

by reticulocytes. Blood 67, Suppl. 1: 49a, 1986. 51. Laskey JD, Ponka P, Schulman HM. Control of ferritin gene expression in differentiating

Friend erythroleukemia cells. Blood 67, Suppl. 1: 190a, 1986. 52. Laskey JD, Ponka P, Schulman HM. Regulation of ferritin biosynthesis in differentiating

Friend erythroleukemia cells. Proceedings of the Eighth International Conference on Proteins of Iron Transport and Storage, Le Chateau Montebello (Quebec), p. 29, May 10-14, 1987.

53. Schulman HM, Wilczynska A, Gauthier Y, Ponka P, Shyamala G. Transferrin receptor

and ferritin levels in murine mammary glands during pregnancy and lactation. Proceedings of the Eighth International Conference on Proteins of Iron Transport and Storage, Le Chateau Montebello (Quebec), p. 69, May 10-14, 1987.


30

54. Baker E, Richardson D, Gross S, Wong A, Grady RW, Ponka P, Hider R,

Kontoghiorghes G, Peter H, Nozoe S. Evaluation of new iron chelators in the hepatocyte in culture. Proceedings of the Eighth International Conference on Proteins of Iron Transport and Storage, Le Chateau Montebello (Quebec), p. 143, May 10-14, 1987.

55. Ponka P. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogues: A new group of

effective chelators. Proceedings of the 6th International Symposium on Trace Elements in Man and Animals, Pacific Grove (California), p. 12, May 31-June 5, 1987.

56. Brittenham GM, Gordeuk VR, Ponka P, Pootrakul P, Fucharoen S, Wasi P, Finch CA.

Iron secretion after oral administration of pyridoxal isonicotinoyl hydrazone (PIH) to patients with iron overload. Abstract presented at the Workshop on the Development of Oral Iron Chelating Agents. Herakleion (Crete), October 20, 1987.

57. Richardson DR, Baker E, Vitolo L, Webb J, Ponka P. Evaluation of analogues of

pyridoxal isonicotinoyl hydrazone for iron chelation therapy. Proceedings of the Twenty Sixth Meeting of the Australian Society for Medical Research, p. 51, December 13-16, 1987.

58. Ponka P, Schulman HM. Mechanism and control of iron uptake by erythroid and non-

erythroid cells. In: Plasma Membrane Oxidoreductases in Control of Animal and Plant Growth (eds. Crane FL, Morré DJ, Löw H) Plenum Press, N.Y. & London, pp. 115-116, 1988.

59. Garrick M, Nakeeb A, Hoke J, Ponka P, Garrick L. Reticulocytes from Belgrade rats

utilize iron delivered by a chelator much more effectively than by transferrin. Blood 72, Suppl. 1: 42a, 1988.

60. Chan R, Schulman HM, Ponka P. Distinct controls of transferrin receptor expression in

erythroid and non-erythroid cells. J Cell Biochem Suppl. 13C: 24, 1989. 61. Nestel FP, Greene R, Ponka P, Seemayer TA, Lapp WS. Macrophage-mediated cytostasis

and iron loss from target cells during graft-versus-host reactions. FASEB J 3: A1127, Abst. No. 5234, 1989.

62. Wu D, Monette FC, Ponka P. Mechanism of action of hemin at early stages of

multipotential cell growth in vitro: Role of hemin as a supplier of iron in serum-deprived marrow. Blood 74, Suppl. 1: 319a, 1989.

62a. Monette FC, Wu D, Ponka P. Mechanism of action of hemin at early stages of

multipotential cell growth in vitro: Role of hemin as a supplier of iron in serum-deprived marrow cultures. Exp Hematol 18: 554, 1990.

63. Garrick LM, Gniecko K, Hoke JE, Al-Nakeeb A, Ponka P, Garrick MD. Alterations in

iron, heme and globin metabolism in Belgrade rat reticulocytes after iron delivery by a synthetic iron chelator. Exp Hematol 18: 573, 1990.


31

64. Ponka P, Richardson D, Schulman HM, Baker E. Pyridoxal isonicotinoyl hydrazone

(PIH) and related acylhydrazones: Promising chelating agents for iron overload treatment. Plzen Medical Report Suppl 62: 121-123, 1990.

65. Chan R, Schulman HM, Ponka P. Transferrin receptor-independent but iron-dependent

proliferation of variant Chinese hamster ovary cells. Arquivos de Medicina (Portugal) 5, Suppl. 1: 32, 1991.

66. Baker E, Richardson D, Gross S, Ponka P. Effect of hydrazones of pyridoxal,

salicylaldehyde and 2-hydroxy-1-naphthylaldehyde on iron metabolism in hepatocytes in culture. Arquivos de Medicina (Portugal) 5, Suppl. 1: 33, 1991.

67. Ponka P, Chan RYY, Schulman HM. Transferrin receptor mRNA regulation during

erythroid differentiation. J Cell Biochem Suppl. 16C, 99, Abst. No. M425, 1992. 68. Ponka P. Physiology of iron-chelation therapy in iron overload. Abstracts of the 3rd NIH

Sponsored Symposium on "The Development of Iron Chelators for Clinical Use", Gainsville, FL, p. 2, May 20-22, 1992.

69. Richardson D, Cikrt M, Schulman HM, Baker E, Ponka P. Effect of hydrazones of

pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthyl-aldehyde on iron metabolism in hepatocytes and on biliary iron excretion. Abstracts of the 3rd NIH Sponsored Symposium on "The Development of Iron Chelators for Clinical Use", Gainsville, FL, p. 29, May 20-22, 1992.

70. Chan RYY, Schulman HM, Ponka P. The expression of ferrochelatase mRNA in

erythroid and nonerythroid cells. Blood 80, Suppl. 1: 275a, 1992. 71. Ponka P, Chan RYY, Schulman HM. Regulation of transferrin receptor mRNA

expression: Distinct regulatory features in erythroid cells. Blood 80, Suppl. 1: 340a, 1992.

72. Ponka P, Schulman HM. Distinct features of iron metabolism in erythroid cells:

Implications for heme synthesis regulation. Proceedings of the Eleventh International Conference on Iron and Iron Proteins, Jerusalem (Israel), p. 40, May 2-7, 1993.

73. Richardson DR, Ponka P. Examination of the ferric ammonium citrate-sensitive iron

uptake process from transferrin. Identification of a redox mechanis. Proceedings of the Eleventh International Conference on Iron and Iron Proteins, Jerusalem (Israel), p. 48, May 2-7, 1993.

74. Ponka P, Nagy E, Schulman HM. Nitric oxide (NO): A possible regulator of IRE-BP

activity and transferrin receptor and ferritin expressions. Proceedings of the Eleventh International Conference on Iron and Iron Proteins, Jerusalem (Israel), p. 53, May 2-7, 1993.


32

75. Ponka P. An overview of human iron metabolism. Proceedings of the Seventy Sixth

Canadian Society for Chemistry Conference, Sherbrooke (Quebec), Abstr. No. 304, May 30-June 3, 1993.

76. Ponka P, Xu WH, Schulman HM. Effect of inflammatory cytokines on ferritin synthesis

in HL-60 cell-derived macrophages. Anstracts of the Sixteenth Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Montreal (Quebec), Abstr. No. 101, July 11-16, 1993.

77. Blaha K, Nerudova J, Jehlickova H, Cikrt M, Ponka P. The efficiacy of aromatic

hydrazones in mobilization of trivalent metals. Presented at the Fourth International Symposium on Chelating Agents in Pharmacology, Toxicology and Therapeutics, Pilsen, CR, August 3-5, 1993. Plzen Medical Report Suppl. 68: 107, 1993.

78. Necas E, Ponka P. Hemin influences expression of the erythropoietin gene. Exp Hematol

21: 1086, 1993. 79. Chan RYY, Schulman HM, Ponka P. Transferrin receptor independent proliferation of

variant Chinese hamster ovary cells. Can J Physiol Pharmacol 72: Aii, 1993. 80. Kichian K, Nestel FP, Green RN, Ponka P, Lapp WS. Macrophage production of nitric

oxide during acute graft-versus-host disease. Canadian Society for Immunology Congress, March 1993.

81. Richardson DR, Neumannova V, Ponka P. The mechanism of iron uptake from

transferrin by neuroblastoma cells and the effect of iron chelators on these processes. Blood 82, Suppl. 1: 459a, 1993.

82. Richardson DR, Neumannova V, Nagy E, Ponka P. Effect of nitric oxide species on

cellular proliferation and transferrin and iron uptake by erythroleukemia (K562) cells. Blood 82, Suppl. 1: 9a, 1993.

83. Vyoral D, Ponka P. A kinetic study of the intermediary pool of iron in rabbit

reticulocytes. Blood 82, Suppl. 1: 461a, 1993. 84. Vyoral D, Schulman HM, Ponka P. Role of iron in the control of erythroid δ-

aminolevulinic acid (ALA) synthase. Blood 82, Suppl. 1: 8a, 1993. 85. Ponka P, Xu W-H, Schulman HM. Effect of inflammatory cytokines on ferritin synthesis

in the HL-60 cell-derived macrophages. Blood 82, Suppl. 1: 26a, 1993. 86. Nestel FP, Kichian K, Green RN, Ponka P, Lapp WS. Cytostasis mediated by

macrophage-derived nitric oxide during acute graft-versus-host disease. Canadian Society for Immunology Congress, March 1994.

87. Kichian K, Gerard JP, Kim D, Nestel FP, Ponka P, Lapp WS. In vivo evidence for

interferon- accompanying interleukin-12 induction in target organs during acute graft-


33

versus-host-disease. Canadian Society for Immunology Congress, March 1994. 88. Vyoral D, Schulman HM, Ponka P. Iron increases the synthesis of δ-aminolevulinic acid

(ALA) in erythroid cells. La Revista de Investigacion Clinica, Suppl., Abstr. No. 6, April 1994.

89. Richardson DR, Neumannova V, Nagy E, Ponka P. Effect of nitric oxide on the iron

metabolism of neoplastic cells in culture. La Revista de Investigacion Clinica, Suppl., Abstr. No. 6, April 1994.

90. Vyoral D, Schulman HM, Ponka P. Control of heme synthesis in erythroid cells: The

synthesis of erythroid δ-aminolevulinic acid (ALA) synthase requires iron. Cell Biol Internat 18: 421, 1994.

91. Richardson DR, Neumannova V, Ponka P. Congeners of nitrogen monoxide decrease

iron uptake from transferrin but do not mobilise iron from prelabelled neoplastic cells. Blood 84, Suppl. 1: 612a, 1994.

92. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition

of heme synthesis with succinylacetone: Examination of cytoplasmic and mitochondrial intermediates involved in iron metabolism. Blood 84, Suppl. 1: 112a, 1994.

93. Richardson DR, Tran EH, Bradshaw D, Ponka P. Potential of iron chelators of the

pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood 84, Suppl. 1: 613a, 1994.

94. Ponka P. Sideroblastic and dyserythropoietic anemias. Proceedings of the Fifth

Conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, MA, pp. 24-25, April 11-13, 1995.

95. Richardson DR, Tran EH, Bradshaw D, Ponka P. Aroylhydrazone ligands of the

pyridoxal isonicotinoyl hydrazone class inhibit the proliferation of neuroblastoma cells. Proceedings of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, MA, p. 84, Abstr. No. P29, April 11-13, 1995.

96. Richardson DR, Ponka P, Baker E. The effect of desferrioxamine on iron and transferrin

uptake by the human melanoma cell. Proceedings of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, MA, p. 84, Abstr. No. P30, April 11-13, 1995.

97. Richardson DR, Ponka P, Vyoral D. The effect of the heme synthesis inhibitor,

succinylacetone, on the intracellular distribution of iron in rabbit reticulocytes. Proceedings of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, MA, p. 71, Abstr. No. A18, April 11-13, 1995.

98. Vyoral D, Schulman HM, Ponka P. Iron increases the synthesis of -amino-levulinic acid

in erythroid cells: Implications for erythroid heme synthesis regulation. Proceedings of the Fifth Conference of the International Association for the Study of Disorders of Iron


34

Metabolism, Boston, MA, p. 77, Abstr. No. P2, April 11-13, 1995. 99. Richardson DR, Neumannova V, Ponka P. Redox-related species of nitrogen monoxide.

Multiple effects on the iron metabolism of cancer cells. Proceedings of the International Conference on BioIron, Asheville, North Carolina, p. 212, April 16-21, 1995.

100. Kennard ML, Jefferies WA, Gabathuler R, Ponka P, Richardson DR. A novel iron uptake

mechanism mediated by GPI-anchored human melanotransferrin. Proceedings of the International Conference on BioIron, Asheville, North Carolina, p. 75, April 16-21, 1995.

101. Richardson DR, Ponka P, Vyoral D. Intracellular iron transport intermediates in

reticulocytes. Fact or fiction. Proceedings of the International Conference on BioIron, Asheville, North Carolina, p. 87, April 16-21, 1995.

102. Vyoral D, Schulman HM, Ponka P. Role of iron in the control of -amino-levulinic acid

synthase in erythroid cells. Proceedings of the International Conference on BioIron, Asheville, North Carolina, p. 63, April 16-21, 1995.

103. Kichian K, Nestel FP, Ponka P, Lapp W. Lipopolysaccharide triggered interleukin-12

mediates interferon- production during acute graft-versus-host disease. The Ninth International Congress of Immunology, San Francisco, California, Abstr. No. 2556, July 23-29, 1995.

104. Hermes-Lima M, Nagy E, Yan J, Schulman HM, Ponka P. The antioxidant activity of the

iron chelator pyridoxal isonicotinoyl hydrazone (PIH) against •OH-mediated strand breaks to plasmid pUC-18 DNA. Proceedings of the Second Annual Meeting of the Oxygen Society, Pasadena, California, November 16-20, 1995.

105. Blaha K, Cikrt M, Nerudova J, Fornuskova H, Ponka P. Biliary iron excretion in rats

following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 86, Suppl. 1: 300a, 1995.

106. Fuchs O, Ponka P. Role of iron in the control of erythroid 5-aminolevulinic acid synthase

mRNA levels. Blood 86, Suppl. 1: 471a, 1995. 107. Richardson DR, Ponka P. Identification of a mechanism of iron uptake by cells that is

stimulated by hydroxyl radicals generated via the iron-catalyzed Haber-Weiss reaction. Blood 86, Suppl. 1: 632a, 1995.

108. Richardson DR, Neumannova V, Ponka P. Nitrogen monoxide decreases iron uptake

from transferrin but does not mobilise iron from prelabelled neoplastic cells. Proceedings of the Second International Conference on Biochemistry and Molecular Biology of Nitric Oxide, Los Angeles, CA, p. 109, Abstr. No. G4, July 13-17, 1996.

109. Richardson DR, Neumannova V, Nagy E, Ponka P. The effect of redox-related species of

nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Proceedings of the Second International Conference on Biochemistry and Molecular Biology of Nitric Oxide, Los Angeles, CA, p. 110, Abstr.


35

No. G5, July 13-17, 1996. 110. Ponka P. Role of transferrin receptors and erythroid 5-aminolevulinate synthase in

erythroid differentiation. Hematopoiesis-Keystone Symposia on Molecular and Cellular Biology, Tamarron, Colorado, Abstr. No. 416, February 10-16, 1997.

111. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis. Proceedings

of the International Symposium on Iron in Biology and Medicine, Saint-Malo, France, p. 31, June 16-20, 1997.

112. Zhang A-S, Ponka P. Microfilament-dependent trafficking of iron into erythroid cell

mitochondria. Proceedings of the International Symposium on Iron in Biology and Medicine, Saint-Malo, France, p. 106, June 16-20, 1997.

113. Necas E, Jiraskova Z, Sulc K, Hradilek A, Ponka P. Cobalt increases the expression of

transferrin receptors. Proceedings of the International Symposium on Iron in Biology and Medicine, Saint-Malo, France, p. 225, June 16-20, 1997.

114. Richardson DR, Ponka P. Identification of a mechanism of iron uptake by cells that is

stimulated by free radicals produced by the Haber-Weiss reaction. Proceedings of the International Symposium on Iron in Biology and Medicine, Saint-Malo, France, p. 320, June 16-20, 1997.

115. Ponka P, Zhang A-S. Delivery of iron into erythroid cell mitochondria requires endosome

motility. Acta Haematol 98, Suppl. 1: 83, 1997. 116. Kim S, Ponka P. Regulation of NO production in iNOS transfected K562 cells. Acta

Haematol 98, Suppl. 1: 98, 1997. 17. Ponka P. Iron metabolism and overload in humans. International Biometals Symposium,

Calgary, Alberta, August 10-14, 1997. 118. Kim S, Ponka P. The effect of NO and LPS on macrophage iron metabolism. The Fifth

International Meeting on Biology of Nitric Oxide, Kyoto, Japan, September 15-19, 1997. Jap J Pharmacol 75, Suppl. I: 99P, 1997.

119. Kim S, Ponka P. iNOS expression and heme availability. The Fifth International Meeting

on Biology of Nitric Oxide, Kyoto, Japan, September 15-19, 1997. Jap J Pharmacol 75, Suppl. I: 26P, 1997.

120. Lok CN, Ponka P. Role of heme in transferrin receptor expression in erythroid cells.

Blood 90, Suppl. 1: 6a, 1997. 121. Ponka P, Nagy E, Zhang A-S, Koury MJ. Regulation of transferrin receptor expression in

erythroid cells: Erythropoietin does not affect iron-regulatory proteins. Blood 90, Suppl. 1: 6a, 1997.

122. Zhang A-S, Sheftel AD, Hajek J, Ponka P. Delivery of iron into erythroid cell


36

mitochondria requires endosome motility. Blood 90, Suppl. 1: 6a, 1997. 123. Lok CN, Ponka P. Analysis of transferrin receptor promoter activity in erythroid cells.

Blood 90, Suppl. 1: 7a, 1997. 124. Hermes-Lima M, Mauricio AQ, Ponka P. The in vitro antioxidant action of PIH against

2-deoxyribose degradation mediated by iron plus ascorbate. Proceedings of the 27th Annual Meeting of the Brazilian Biochemical Society, March 23-26, 1998.

125. Ponka P, Kim S. Control of transferrin receptor and ferritin expression via nitric oxide

(NO)-mediated degradation of IRP-2. Presented at the Third International Conference on Biochemistry and Molecular Biology of Nitric Oxide, Los Angeles, California, July 11-15, 1998. Nitric Oxide 2: 104, 1998.

126. Hermes-Lima M, Lopes CKB, Santos N, Passos MD, Mauricio AQ, Andrade AQ Jr,

Gonçalves M, Silva TJC Jr, Oliveira R, Souza JR, Yan T, Wang E, Andrews M, Schulman HM, Ponka P. The antioxidant activity of PIH and tannic acid, iron and copper chelators. Proceedings of the 9th Biennial Meeting of the International Society for Free Radical Research, Sao Paulo, Brazil, September 7-11, 1998.

127. Ponka P, Lok CN. The control of transferrin receptor expression during erythroid

differentiation. Exper Hematol 25: 809, 1998. 128. Ponka P. Metabolism and transport of iron: Distinct control mechanisms in erythroid

cells. Proceedings of the NIH Workshop on Iron: From Current Biochemistry to New Chelator Development Strategies, Bethesda, MD, September 21-22, 1998.

129. Ponka P. Iron metabolism: Physiology and pathophysiology. Proceedings of the 5th

Conference of the International Society for Trace Element Research in Humans (ISTERH), Lyon, France, September 26-October 1, 1998. J Trace Elem Exp Med 11: 454, 1998.

130. Ponka P. Iron metabolism and overload in humans. Proceedings of the 39th Annual

Meeting of the American College of Nutrition, Albuquerque, NM, October 103, 1998. 131. Kim S, Ponka P. Evidence that IRP-2 plays a key role in controlling transferrin receptor

and ferritin expression. Blood 92, Suppl.1, Part 1: 326a, 1998. 132. Arduini E, Buss JL, Ponka P. Iron chelation from murine reticulocytes: Structure-activity

relationships among halogenated analogs of pyridoxal isonicotinoyl hydrazone, and effects of albumin on iron efflux. Blood 92, Suppl.1, Part 2: 11b, 1998.

133. Zhang A-S, Gruenheid S, Gros P, Ponka P. The use of Nramp2-transfected Chinese

hamster ovary cells and reticulocytes from mk/mk mice to study iron transport mechanisms. Blood 92, Suppl.1, Part 1: 327a, 1998.


37

134. Ponka P, Lok CN. The control of transferrin receptor expression in erythroid cells.

Presented at INABIS '98 - 5th Internet World Congress on Biomedical Sciences at McMaster University, Canada, December 7-16, 1998. Invited Symposium. Available at URL http://www.mcmaster.ca/inabis98/templeton/ponka0887/index.html.

135. Ponka P. Pathogenesis of sideroblast formation. Invited Lecture: Fifth International

Symposium on Myelodysplastic Syndromes, Prague, CR, April 21-24, 1999. Leukemia Res. 23, Suppl. 1: 124, 1999.

136. Crowe WE, Maglova LM, Ponka P, Russell JM. Iron chelation blocks human

cytomegalovirus (HCMV) induced cell volume increase in MRC-5 fibroblasts. FASEB J 13: A575, 1999.

137. Zhang A-S, Gruenheid S, Gros P, Ponka P. The use of Nramp2-transfected Chinese

hamster ovary cells and reticulocytes from mk/mk mice to study iron transport mechanisms. Proceedings of the World Congress on Iron Metabolism – BioIron '99, Sorrento, Italy, May 23-28, 1999.

138. Lok CN, Ponka P. Transcriptional regulation of transferrin receptor by hypoxia:

Identification of a functional hypoxia-response element in the transferrin-receptor gene. Proceedings of the World Congress on Iron Metabolism – BioIron '99, Sorrento, Italy, May 23-28, 1999.

139. Kim S, Ponka P. IRP-2 plays a crucial role in controlling transferrin receptor and ferritin

expression. Proceedings of the World Congress on Iron Metabolism – BioIron '99, Sorrento, Italy, May 23-28, 1999.

140. Lobmayr L, Killisch I, Sauer T, Wilson RB, Ponka P, Beug H, Muellner EW. Terminal

differentiation in primary erythroblasts leads to coordinate changes in iron metabolism resembling an "iron metabolism switch". Proceedings of the World Congress on Iron Metabolism - BioIron '99, Sorrento, Italy, May 23-28, 1999.

141. Lok CN, Ponka P. Identification of a functional hypoxia-response element in the

transferrin-receptor gene. 28th Annual Meeting of the International Society of Experimental Hematology, Monte Carlo, July 10-13, 1999. Exper Hematol 27, Suppl.1: 91, 1999.

142. Kim S, Ponka P. Effects of interferon- and lipopolysaccharide on macrophage iron

metabolism are mediated by nitric oxide-induced degradation of IRP-2. Blood 94, Suppl.1, Part 1: 192a, 1999.

143. Necas E, Hradilek A, Fuchs O, Povysil C, Ponka P. Cobalt increases the expression of

transferrin receptors. Blood 94, Suppl.1, Part 1: 406a, 1999. 144. Sheftel A, Zhang A-S, Ponka P. Transferrin endocytosis in erythroid cells: A confocal

microscopic study. Blood 94, Suppl.1, Part 1: 402a, 1999.


38

145. Crowe WE, Maglova LM, Ponka P, Russell JM. Iron chelation inhibits cytomegalovirus-

induced up-regulation of a v-type H+ ATPase in MRC-5 fibroblasts. Mol Biol Cell 10, Suppl. S: 464, 1999.

146. Uzuelli FHP, Oliveira RG, Ponka P, Hermes-Lima M. Protective effect of tannic acid

against oxidative stress in mice induced by i.p. injection of iron-NTA. Annual Meeting of the Brazilian Society of Biochemistry and Molecular Biology, May 2000.

147. Kim S, Ponka P. NO-mediated S-nitrosylation targets IRP2 for degradation via ubiquitin-

proteasome system. The First International Conference on Biology, Chemistry and Therapeutic Applications of Nitric Oxide. San Francisco, CA, June 3-7, 2000. Nitric Oxide 4: 315, 2000.

148. Ponka P, Kim S. Nitric oxide-mediated modulation of IRP2 controls transferrin receptor

expression. 28th World Congress of the International Society of Hematology. Toronto, Canada, August 26-30, 2000. Internat J Hematol 72, Suppl.1: 4, 2000.

149. Arduini E, Buss JL, Ponka P. Efficiency of halogenated analogs of pyridoxal

isonicotinoyl hydrazone (PIH) in mobilization of intracellular iron is determined by the membrane permeability of the Fe-chelator complex. 6th International Symposium on Chelating Agents in Pharmacology, Toxicology and Therapeutics, Pilsen, Czech Republic, September 7-9, 2000.

150. Ponka P. Iron targeting to mitochondria in reticulocytes. Millenium Meeting on

Porphyrins and Porphyrias 2000, Institut Pasteur, Paris, France, September 10-13, 2000. 151. Ponka P. Distinct regulation of heme synthesis in erythroid cells: Role of iron. The 5th

International Porphyria-Heme Symposium, Sendai, Japan, October 20-21, 2000. 152. Canonne-Hergaux F, Zhang A-S, Ponka P, Gros P. Characterization of the iron

transporter Nramp2/DMT1 in immature red blood cells: Defective expression in the microcytic anemia (mk/mk) mouse. The 42nd Annual Meeting of the American Society of Hematology, San Francisco, California, December 2000.

153. Ponka P, Kim S. Nitric oxide-mediated S-nitrosylation and the consequent proteasomal degradation of IRP2 controls transferrin receptor expression. Blood 96, Suppl. 1, Part 1: 483a, 2000.

154. Ponka P. Cellular iron metabolism. Clin Chem Lab Med 39: Spec Suppl.: S42, 2001. 155. Canonne-Hergaux F, Zhang A-S, Gros P, Ponka P. Expression of DMT1 (NRAMP2) in

erythroid clels. Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-23, 2001.

156. Richardson DR, Mouralian C, Ponka P, Becker E. Lipophilic chelators that bind

mitochondrial iron: Potential agents for the treatment of Friedreich’a ataxia. Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-


39

23, 2001. 157. Arduini E, Buss JL, Ponka P. The rate of efflux of Fe complexes determines the

efficiency of pyridoxal isonicotinoyl hydrazone (PIH) analogs at mobilizing cellular iron. Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-23, 2001.

158. Kim S, Ponka P. S-Nitrosylation of IRP2 leads to its proteasomal degradation:

Consequences for macrophage iron metabolism. Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-23, 2001.

159. Buss JL, Arduini E, Shephard KC, Ponka P. Lipophilicity of pyridoxal isonicotinoyl

hydrazone (PIH) analogs determines their toxicity toward K562 erythroleukemia cells. Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-23, 2001.

160. Buss JL, Neuzil J, Gellert N, Weber C, Ponka P. Does the toxicity of pyridoxal

isonicotinoyl hydrazone (PIH) analogs involve oxidative stress caused by their Fe complexes? Proceedings of the World Congress on Iron Metabolism - BioIron 2001, Cairns, Australia, August 18-23, 2001.

161. Kim S, Ponka P. Control of ferritin expression via NO-mediated modulation of IRP2:

Implication for cellular iron homeostasis. Proceedings of the World Congress on Iron Metabolism - Bioiron 2001, Cairns, Australia, August 18-23, 2001.

162. Sheftel A, Kim S, Ponka P. Up-regulation of heme oxygenase-1 by a non-heme inducer

does not cause an increase in ferritin synthesis. Proceedings of the World Congress on Iron Metabolism - Bioiron 2001, Cairns, Australia, August 18-23, 2001.

163. Ponka P. Overview of iron metabolism. The 34th International Congress of Physiological

Sciences, Christchurch, New Zealand, August 26-31, 2001. 164. Ponka P. Recent advances in cellular iron metabolism. J Trace Elem Exper Med 14: 362,

2001. 165. Ponka P. Role of nitric oxide in cellular iron metabolism. Proceedings of the Second

International Workshop on Iron and Copper Homeostasis, Pucon, Chile, November 10-13, 2001.

166. Ponka P, Yoon H-S, Kim S. Overexpression of transferrin receptor 2 inhibits erythroid

differentiation of murine erythroleukemia cells. Blood 98, Suppl. 1, Part 1: 5a, 2001. 167. Ponka P, Kim S. Control of ferritin expression via nitric oxide modulation of iron

regulatory protein 2. Blood 98, Suppl. 1, Part 1: 747a, 2001. 168. Buss JL, Neuzil J, Ponka P. Does the toxicity of pyridoxal isonicotinoyl hydrazone (PIH)

analogs involve oxidative stress caused by their Fe complexes? Blood 98, Suppl. 1, Part 2: 4b, 2001.


40

169. Ponka P, Sheftel AD, Zhang A-S. Iron targeting to mitochonria in erythroid cells. Third

International Biometals Symposium, King’s College London, London, U.K., April 11-13, 2002.

170. Kim S, Ponka P. Control of ferritin expression via nitric oxide modulation of iron

regulatory protein 2. Third International Biometals Symposium, King’s College London, London, U.K., April 11-13, 2002.

171. Buss JL, Neuzil J, Ponka P. Induction of apoptosis by iron chelators. Third International

Biometals Symposium, King’s College London, London, U.K., April 11-13, 2002. 172. Buss JL, Neuzil J, Ponka P. The role of oxidative stress in the toxicity of pyridoxal

isonicotinoyl hydrazone (PIH) analogs. Third International Biometals Symposium, King’s College London, London, U.K., April 11-13, 2002.

173. Kim S, Ponka P. Nitric oxide-mediated post-transcriptional regulation of ferritin in

macrophage. The 2nd International Conference on Heme Oxygenase and Cellular Stress Response, Catania, Italy, June 3-6, 2002.

174. Sheftel A, Kim S, Ponka P. Up-regulation of heme oxygenase-1 by a non-heme inducer is

not associated with an apparent degradation of cellular heme. The 2nd International Conference on Heme oxygenase and Cellular Stress Response, Catania, Italy, June 3-6, 2002.

175. Kim S, Ponka P. S-nitrosylation of IRP2 regulates its stability via ubiquitin-proteasomal

pathway. 2nd International Conference on Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Prague, Czech Republic, June 16-20, 2002. Nitric Oxide 6: 410, 2002.

176. Kim S, Ponka P. Nitrogen monoxide-mediated control of ferritin synthesis: Implications

for macrophage iron homeostasis. 2nd International Conference on Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Prague, Czech Republic, June 16-20, 2002. Nitric Oxide 6: 410, 2002.

177. Kim S, Yoon H-S, Ponka P. Transferrin receptor 2 inhibits heme synthesis in erythroid

cells. 31st Annual Meeting of the International Society for Experimental Hematology, Montreal, Quebec, Canada, July 5-9, 2002. Exper Hematol 30, Suppl.1: 43, 2002.

178. Kim S, Ponka P. Nitric oxide increases ferritin synthesis in macrophages and changes

cellular iron distribution: Molecular mechanism of anemia of chronic disorders. 31st Annual Meeting of the International Society for Experimental Hematology, Montreal, Quebec, Canada, July 5-9, 2002. Exper Hematol 30, Suppl.1: 102, 2002.

179. Monge A, Kim S, Sheftel A, Ponka P, Gassmann M. The effect of continuous

overexpression of erythropoietin on iron metabolism in mice. Blood 100, Suppl. 1, Part 1: 6a, 2002.


41

180. Sheftel A, Zhang A-S, Shirihai O, Ponka P. Transfer of iron from transferring endosomes to mitochondria in erythroid precursors: Biochemical and microscopic evidence for a kiss and run mechanism. Blood 100, Suppl. 1, Part 1: 7a, 2002.

181. Hershko C, Link G, Konijn AB, Breuer W, Cabantchik IZ, Ponka P. Combined treatment

with pyridoxal isonicotinoyl hydrazone (PIH) analogs and desferrioxamine produces a shuttle effect improving chelating response. Blood 100, Suppl.1, Part 1: 8a, 2002.

182. Kim S, Ponka P. Role of nitric oxide in iron-mediated degradation of iron regulatory

protein 2. Blood 100, Suppl.1, Part 1: 444a, 2002. 183. Zhang A-S, Ponka P. Anemia of hbd/hbd mice is caused by reduced rate of transferrin

cycling. Blood 100, Suppl.1, Part1: 445a, 2002. 184. Pastore YD, Divoky V, Liu E, Ponka P, Semenza GL, Prchal JT. Defective yolk sac

erythropoiesis in HIV-1∀-null mice: A role of iron. Blood 100, Suppl.1, Part 1: 717a, 2002.

185. Ponka P, Kim S. Role of nitric oxide in iron-mediated degradation of iron regulatory

protein 2. FASEB J 17 Pt. 2, Suppl. S: A1084, 2003. 186. Sheftel AD, Kim S, Ponka P. Non-heme induction of HO-1 does not apparently alter

cellular iron levels. Proceedings of the World Congress on Iron Metabolism – Bioiron 2003, National Institutes of Health, Bethesda, Maryland, p. 212, May 4-9, 2003.

187. Monge A, Kim S, Sheftel A, Ponka P, Gassmann M. Continuous overexpression of

erythropoietin alters iron metabolism in mice. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 217, May 4-9, 2003.

188. Zhang A-S, Ponka P. Reduced rate of transferring cycling causes anemia of hbd/hbd

mice. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 220, May 4-9, 2003.

189. Pastore YD, Divoky V, Liu E, Ponka P, Semenza GL, Prchal JT. Defective yolk sac

erythropoiesis in HIF-1α-null mice: A role of iron. Proceedings of the World Congress on Iron Metabolism – Bioiron 2003, National Institutes of Health, Bethesda, Maryland, p. 221, May 4-9, 2003.

190. Crowe W, Maglova L, Reeves A, Ponka P, Russell J. Iron chelation inhibits

cytomegalovirus-induced recovery of host cell mitochondrial transmembrane potential. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 241, May 4-9, 2003.

191. Yoon H-S, Lok N, Kim S, Ponka P. Overexpression of transferrin receptor 2 inhibits

erythroid differentiation of murine erythroleukemia cells. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 298, May 4-9, 2003.


42

192. Kim S, Ponka P. Nitric oxide appears to play a role in iron-mediated degradation of iron

regulatory protein 2. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 298, May 4-9, 2003.

193. Sheftel AD, Zhang A-S, Shirihai O, Ponka P. Kiss and run: The route of iron from

endosomes to mitochondria can bypass the cytosol in hemoglobin-producing cells. Proceedings of the World Congress on Iron Metabolism – BioIron 2003, National Institutes of Health, Bethesda, Maryland, p. 299, May 4-9, 2003.

194. Zhang A-S, Ponka P. Reduced rate of transferrin cycling causes anemia of hbd/hbd mice.

Exper Hematol 31, 7, Suppl. 1: 160, 2003. 195. Ponka P. Overview of iron metabolism. Proceedings of the 13th International Conference

on Oral Chelation in the Treatment of Thalassaemia and Other Diseases, Prague, Czech Republic, July 12-15, 2003.

196. Sheftel AD, Zhang A-S, Shirihai O, Ponka P. Highly efficient heme synthesis in

erythroid cells requires a direct transfer of iron from transferrin endosomes to mitochondria. Proceedings of the International Conference on Porphyrins and Porphyrias 2003, Prague, Czech Republic, September 21-24, 2003. Physiol Res 52: 245, 2003.

197. Ponka P. Overview of cellular iron metabolism: The crucial role of heme oxygenase in

recycling heme iron. Proceedings of the International Conference on Heme Oxygenase, Uppsala, Sweden, September 28-October 3, 2003.

198. Sheftel AD, Kim S, Ponka P. Induction of heme oxygenase-1 by “oxidative stress” does

not apparently increase cytosolic iron levels. Proceedings of the Ingternational Conference on Heme Oxygenase, Uppsala, Sweden, September 28-October 3, 2003.

199. Priwitzerova M, Pospisilova D, Prchal JT, Hlobilkova A, Mihal V, Indrak K, Ponka P,

Divoky V. The first human mutation of DMT1 (Nramp2) causes severe defect of erythropoiesis that can be rescued in vitry bo Fe-SIH. Blood 102, Suppl. 1, Part 1: 562, 2003.

200. Pastore YD, Liu E, Divoky V, Ponka P, Semenza G, Prchal JT. The erythropoietic defect

in the HIF-1 alpha -/- animals is primarily related to disruption in iron metabolism. Blood 102, Suppl. 1, Part 1: 5752, 2003.

201. Prchal JT, Pospisilova D, Mims MP, Priwitzerova M, Indrak K, Ponka P, Guan Y,

Divoky V. Identification of the first human mutation of DMT1 (Nramp2) in a patient with microcytic anemia and iron overload. Blood 102, Suppl. 1, Part 1: 754a, 2003.

202. Kim S, Ponka P. The molecular mechanism of nitric oxide-mediated downregulation of

iron uptake from transferrin. Blood 102, Suppl. 1, Part 1: 758a, 2003. 203. Rivas-Estilla AM, Fillebeen C, Bisaillon M, Ponka P, Muckenthaler M, Hentze A,

Koromilas A, Pantopoulos K. Iron inactivates the RNA polymerase of hepatitis C virus


43

and inhibits subgenomic viral replication in Huh7 cells. Proc of the 10th Internat Meet on hepatitis C virus, and Related Viruses, Kyoto, Japan, December 2003.

204. Shefel AD, Zhang A-S, Ponka P. Kiss and run: Iron is delivered to the site of heme

synthesis in erythroid cells through a transient endosome-mitochondria interaction. Can Repir J 11: 250, 2004.

205. Sheftel AD, Kim S, Ponka P. Induction of heme oxygenase-1 by “oxidative stress” does

not apparently increase cytosolic iron levels. 4th Scientific Meeting of the Oxidative Stress Consortium, May 21-23, 2004.

206. Mikhael M, Kim S, Ponka P. The role of nitric oxide in iron metabolism; Nitric oxide

mediates specific increase of ferritin synthesis independently of iron regulatory proteins. 4th Scientific Meeting of the Oxidative Stress Consortium, May 21-23, 2004.

207. Nie G, Kim S, Sheftel A, Ponka P. Overexpression of mitochondrial ferritin induces

apparent iron starvation and changes cellular iron distribution. 4th Scientific Meeting of the Oxidative Stress Consortium, May 21-23, 2004.

208. Szuber N, Buss J, Trudel M, Ponka P. Iron chelators improve the pathophysiology of β-

thalassemic erythrocytes in vitro and in vivo. 4th Scientific Meeting of the Oxidative Stress Consortium, May 21-23, 2004.

209. Ponka P. “Why grasse is greene, or why our blood is red . . .” (John Donne, 1572-1631).

Presented at Twenty-Second World Congress of Czechoslovak Society of Arts and Sciences. Olomouc Czech Republic, June 26-July 4, 2004.

210. Ponka P. Recent advances in iron metabolism. Seventh International Symposium on

Chelating Agents in Biomedicine, Toxicology and Therapeutics. Pilsen, Czech Republic, July 8-11, 2004. Biomark Environ 2: 35, 2004.

211. Pokorna A, Nerudova J, Kasparova L, Knotkova L, Ponka P, Cikrt M. The effect of

pyridoxal isonicotinoyl hydrazone (PIH) analogues on mobilization of aluminum in rats. Seventh International Symposium on Chelating Agents in Biomedicine, Toxicology and Therapeutics. Pilsen, Czech Republic, July 8-11, 2004, Biomark Environ 2:55, 2004.

212. Simunek T, Sterba M, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Hrdina R,

Gersl V, Cermakova E, Ponka P. Pyridoxal isonicotinoyl hydrazone – a potent lipophilic iron chelator reduces daunorubicin-induced toxicity in rabbits. Seventh International Symposium on Chelating Agents in Biomedicine, Toxicology and Therapeutics. Pilsen, Czech Republic, July 8-11, 2004. Biomark Environ 2:59, 2004.

213. Sterba M, Simunek T, Mazurova Y, Adamcova M, Kaplanova J, Cermakova E, Gersl V,

Ponka P. Tolerability study of repeated administration of pyridoxal o-chlorobenzoyl hydrazone (a novel iron chelator) in rabbits. Seventh International Symposium on Chelating Agents in Biomedicine, Toxicology and Therapeutics. Pilsen, Czech Republic, July 8-11, 2004, Biomark Environ 2: 60, 2004.


44

214. Kim S, Wing S, Ponka P. Role of nitric oxide in macrophage iron homeostasis. Immunology 2004, Montreal, QC, July 18-23, 2004. Clin Invest Med 27: 38B, 2004.

215. Ponka P. Erythroid cell iron metabolism: Lessons from genetic defects in mice and men.

Proceedings of the Australian Health and Medical Research Congress, Sydney, November 21-26, 2004.

216. Priwitzerova M, Pospisilova D, Indrak K, Ponka P, Divoky V. Consequences of DMT1

mutation on proliferation and hemoglobinization of erythroid progenitors in vitro. Blood 104, Suppl. 1, Part 1: 871a, 2004.

217. Sheftel AD, Zhang A-S, Shirihai O, Ponka P. Iron acquisition in reticulocytes: Evidence

for a kiss and run mechanism. Blood 104, Suppl. 1, Part 1: 871a, 2004. 218. Szuber N, Buss JL, Trudel M, Felfy H, Ponka P. Novel iron chelators alleviate symptoms

of thalassemia. Blood 104, Suppl. 1, Part 1: 873a, 2004. 219. Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes

cytosolic iron starvation and changes cellular iron homeostasis. Blood 104, Suppl. 1, Part 1: 873a, 2004.

220. Lok C-N, Ponka P. Stimulation of transferrin receptor expression by enhanced heme

biosynthesis in murine erythroleukemia cells. Blood 104, Suppl. 1, Part 1: 874a, 2004. 221. Monge A, Kim S, Sheftel A, Ponka P, Gassmann M. Disturbances of iron metabolism in

mice overexpressing erythropoietin. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 6).

222. Priwitzerova M, Pospisilova D, Ponka P, Divoky V. Defective growth and

hemoglobinization of DMT1 mutant erythroid progenitors in vitro. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 6).

223. Gunagjun N, Sheftel A, Kovac E, Ponka P. Effects of expression of mitochondrial ferritin

on iron metabolism and heme biosynthesis in mammalian cells. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 13).

224. Priwitzerova M, Pospisilova D, Sheftel A, Divoky V, Ponka P. Functional consequences

of the human DMT1 mutation on protein expression and iron uptake. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 33).

225. Nie G, Chen G, Pantopoulos K, Ponka P. Effects of mitochondrial ferritin expression on

tumor iron metabolism and repression of tumor growth in nude mice xenografts. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 45).


45

226. Mikhael M, Kim S, Schranzhofer M, Mullner E, Ponka P. Nitric oxide upregulates

ferritin synthesis independently of iron regulator protein-iron response element binding activity. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 46).

227. Soe-Lin S, Sheftel A, Ponka P. The effects of various forms of exogenous iron on the

macrophage labile iron pool. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 77).

228. Simunek T, Sterba M, Popelova O, Boere C, Musters RJP, Ponka P, Gersl V. Iron

chelation for protection against oxidative stress-induced myocardial injury. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 89).

229. Wang G, Adrian Z, Trask HW, Gorman N, Szakacs JG, Dwyer BE, Yohe HC, Balestra

D, Sinclair JF, Ponka P, Sinclair PA. Ferric nitriloatriacetate and other iron chelates for iron loading, cell distribution and toxicity in liver cell cultures. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 89).

230. Sterba M, Popelova O, Kovarikova P, Simunek T, Vavrova K, Ponka P, Gersl V. Pilot

study on plasma pharmacokinetics of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 98).

231. Szuber N, Trudel M, Soe-Lin S, Felfy H, Buss JL, Ponka P. Novel iron chelators alleviate

symptoms of β-thalassemia. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 99).

232. Pokorna A, Nerudova J, Kasparova L, Knotkova J, Ponka P, Cikrt M. The effect of

PMBH (107) on mobilization of iron – influence of iron overload. Proceedings of the First Congress of the International BioIron Society – BioIron 2005, Prague, Czech Republic, May 22-26, 2005 (p. 109).

233. Ponka P. Iron: Our friend and foe. Third Joint Meeting of the Society for Free Radical

Research of Australasia and Japan. Gold Coast, Queensland, Australia, December 2-5 2005.

234. Nie G, Chen G, Sheftel A, Pantopoulos K, Ponka P. Effects of mitochondrial ferritin

expression on tumor iron metabolism and tumor growth in nude mice xenografts. Blood 106, Suppl 1 (part 1): 999a, 2005.

235. Mikhael M, Kim S, Schranzhofer M, Mullner E, Ponka P. Nitric oxide upregulates

ferritin synthesis independently of iron regulatory protein-iron responsive element binding activity. Blood 106, Suppl 1 (part 1): 1002a, 2005.

236. Priwitzerova M, Pospisilova D, Nie G, Sheftel A, Prchal JT, Divoky V, Ponka P. DMT1


46

mutation in a patient with hypochromic microcytic anemia: Functional consequences and response to erythropoietin. Blood 106, Suppl 1 (part 1): 1000a, 2005.

237. Ponka P, Kim S, Richardson DR. Nitrogen monoxide and carbon monoxide dramatically

modulate cellular and molecular iron metabolism. Eur J Clin Invest 36 (Suppl1): 69, 2006.

238. Richardson DR, Watts RN, Hawkins C, Ponka P. Nitric oxide release from cells is mediated by active transport via MRP1. Nitric Oxide 14: 3, 2006. 239. Ponka P, Mikhael M, Kim SF, Schranzhofer M, Soe-Lin S, Sheftel AD, Mullner EW.

Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide. Nitric Oxide 14: 33, 2006.

240. Whitnall M, Paccio H, Koening M, Ponka P, Richardson DR. A mitochondrial permeable

iron chelator prevents the cardiac hypertrophy observed in the Frda/MCK knockout mouse: A novel therapeutic strategy. Proceedings of the Third International Friedrich’s Ataxia Scientific Conference, National Institutes of Health, Bethesda, Marryland, November 10-12, 2006.

241. Sheftel AD, Zhang A-S, Brown C, Shirihai OS, Ponka P. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 108, Suppl 1 (Part 1): 832, 2006 242. Soe-Lin S, Buss JL, Tang E, Ponka P. Calcein and the labile iron pool. Blood 108, Suppl

1 (Part 1): 4442, 2006. 243. Sheftel AD, Zhang AS, Brown C, Shirihai O, Ponka P. Interorganellar association

mediates the efficient transfer of iron from endosome to mitochondria. FASEB J 21: A1348, 2007.

244. Mikhael M, Kim SF, Schranzhofer M, Soe-Lin S, Shefter AD, Mulllner, Ponka P. Nitric

oxide (NO+) enhances ferritin synthesis by boty IRP-dependent and -independent mechanisms. Amer J Hematol 82: 522, June 2007.

245. Sheftel AD, Kahawita T, Zhang AS, Brown C, Shirihai O, Ponka P. Amer J Hematol 82:

523, 2007. 246. Schranzhofer M, Schifrer M, Ponka P, Mullner EW. Low cytosolic now-heme iron

levels in erythroid cells prevent IRP2-mediated ferritin upregulation during differentiation. Amer J Hematol 82: 523-524, 2007.

247. Rathore KI, Kerr B, Lopez-Vales R, Ponka P, David S. Ceruloplasmin and the iron-

hemeostatic response to spinal cord injury. Amer J Hematol 82: 534-535, 2007. 248. Nie G, Lu Z, Soe-Lin S, Zhao B, Ponka P. Overexpression of mitochondrial ferritin

sensitizes cultured cells to oxidative stress via an iron-mediated mechanism. Amer J Hematol 82: 545, 2007.


47

249. Jeong SY, Ponka P, David S. Iron regulates ferroportin1 localization to lipid rafts. Amer J Hematol 82: 588-589, 2007.

250. Soe-Lin S, Sheftel A, Ponka P. The role of NRAMP1 in erythrophagocytosis. Amer J

Hematol 82: 593-594, 2007. 251. Sheftel AD, Kim SF, Ponka P. The cytoprotective mechanism of heme oxygenase-1 does

not entail an alteration in cellular iron metabolism. Amer J Hematol 82: 603-604, 2007. 252. Ponka P. Iron and heme: their exquisite relationship makes blood red. Proceedings of

the Intenational Conference on Porphyrims and Porphyrias, Rotterdam, The Netherlands, April 29-May 3, p. 17, 2007.

253. Heme and iron: our friends and foes. Proceedings of the 5th International Congress on

Heme Oxygenases, Krakow, Poland, September 5-9, p. 30, 2007. 254. Sheftel AD, Kim SF, Ponka P. Increased levels of heme oxygenase-1 reduce the

generation of reactive oxygen species without affecting iron metabolism. Proceedings of the 5th International Congress on Heme Oxygenase, Krakow, Poland, p. 124, 2007.

255. Simunek T, Kaiserova H, Sterba M, Popelova O, Adamcova M, Ponka P, Gergl V. Study

of protection by salicylaldehyde isonicotinoyl hydrazone against hydrogen peroxide- and anthracycline-induced toxicity to cardiac cells. Circ Res 101: E72, 2007.

256. Sheftel A, Kahawita T, Zhang A, Brown CM, Shirihai OS, Ponka P. Interorganellar

from endosomes to mitochondria in erythroid cells. Exp Hematol 35: 105-105, Suppl. 2, 2007.

257. Schranzhofer M, Schifrer M, Galy B, Hentze M, Ponka P, Muellner EW. Low cytosolic

non-heme iron levels in erythroid cells prevent IRP2-mediated ferritin upregulation during differentiation. Exp Hematol 35: 108-109, Suppl. 2, 2007.

258. Schranzhofer M, Schifrer M, Ponka P, Muellner EW. Modulation of IRP binding activity

by oxygen in primary erythroid cells. Blood 110 Suppl 1 (Part 1): 7832, 2007. 259. Soe-Lin S, Sheftel AD, Ponka P. The role of Nramp1 in erythrophagocytosis. Blood 110

(Suppl 1) Part 2: 31B, 2007. 260. Ponka P, Sheftel AD, Pantopoulos K, Nie G. The role of mitochondrial ferritin in iron

metabolism in normal and neoplastic cells. 1st International Conference RAHMS: Recent Advances in Health and Medical Sciences, Paphos, Cyprus, March 7-12, 200

Prem Ponka Miscellaneous Professional Activities

48

A. Invited Conference Papers 1973 International Conference on Porphyrin and Heme Synthesis, Marburg, Germany. 1974 Fourth International Conference on Erythropoiesis, Tokyo, Japan. 1976 Ciba Foundation Symposium on Iron Metabolism, London, England. 1979 Fourth International Conference on Proteins of Iron Storage and Transport, Davos, Switzerland. 1983 Sixth International Conference on Proteins of Iron Storage and Transport, Sapporo, Japan: Session Chairman. 1985 International Conference on "Porphyrins and Porphyrias", Paris, France. 1986 Gordon Research Conference on Chemistry and Biology of Pyrrole Compounds,Wolfeboro, New Hampshire. 1987 Sixth International Symposium on Trace Elements in Man and Pacific Grove California. 1987 Ciba Foundation Discussion Meeting on Iron Chelators, London, U.K. Invited Discussant.

1988 NATO Advanced Research Workshop on Plamsa Membrane Oxidoreductase in Control of Animal and Plant Growth, Cordoba, Spain.

1990 Third International Symposium on Chelating Agents in Pharmacology, Toxicology and Therapeutics, Pilsen, Czechoslovakia: Session Chairman. 1990 European Iron Club Meeting, Porto, Portugal: Session Chairman. 1992 The Third NIH Sponsored Symposium on the Development of Iron Chelators for Clinical Use, Gainesville, Florida. 1992 The Conference Celebrating the 40th Anniversary of the Institute of Hematology and Blood Transfusion, Prague, Czechoslovakia. 1993 Eleventh International Conference on Iron and Iron Proteins, Jerusalem, Israel: Invited Keynote Speaker and Session Chairman. 1993 Seventy-Sixth Canadian Society for Chemistry, Sherbrooke, Quebec. 1993 Sixteenth Symposium of the International Association for Comparative Research on Leukemia and related Diseases, Montreal, Quebec: Session Chairman.


49

1994 Twenty-Fifth Congress of the International Society of Hematology, Cancun, Mexico 1995 Fifth Conference of the International Association for the Study of Disorders of Iron

Metabolism, Boston, Massachusetts. 1995 International Conference on Bioiron (ICBI), Asheville, North Carolina: Session

Chairman. 1996 1996 Meeting of Industrial Toxicology to Commemorate Professor Teisinger, J.E.

Purkinje Czech Medical Society, Prague, Czech Republic. 1997 International Symposium on Iron in Biology and Medicine, Saint-Malo, France. 1997 Porphyrins and Porphyrias '97, Hamburg, Germany, Session Chairman. 1997 International Biometals Symposium (IBS), Calgary, Alberta, Canada. 1998 Eleventh Biennial Scientific Meeting of the Asian-Pacific Association for the Study of

the Liver, Perth, Western Australia. 1998 International Conference on Molecular Mechanisms of Iron Homeostasis in Health and

Disease, Jerusalem, Israel. 1998 NIH-Sponsored Workshop on Iron: From Current Biochemistry to New Chelator

Development Strategies, NIH, Bethesda, MD. 1998 Fifth Conference of the International Society for Trace Element Research in Humans

(ISTERH), Lyon, France. 1998 Thirty Ninth Annual Meeting of the American College of Nutrition, Albuquerque, NM. 1998 Panhellenic Congress of Hematology, Crete, Greece. 1999 Fifth International Symposium on Myelodysplastic Syndromes, Prague, CR. 1999 Biolron '99 Congress, Sorrento, Italy: Invited Speaker and Session Chairman. 1999 First International Workshop on Iron and Copper Homeostasis, Pucon, Chile. 2000 28th World Congress of the International Society of Hematology, Toronto, Canada;

Session Chairman 2000 Fifth International Porphyria-Heme Symposium, Sendai, Japan; Keynote Speaker 2000 Sixth International Symposium on Chelating Agents in Pharmacology, Toxicology and

Therapeutics, Pilsen, Czech Republic.


50

2000 Millenium Meeting on Porphyrins and Porphyrias 2000, Paris, France. 2001 14th International Congress of Clinical Chemistry and Laboratory Medicine, Prague,

Czech Republic. 2001 Roche Diagnostics Workshop on Hematological and Biochemical Diagnostics of

Disturbances of Iron Metabolism and Erythropoiesis. AACC CSCC 2001 - Annual Meeting and Clinical Lab. Expo., Chicago, Illinois.

2001 Biolron 2001 Congress, Cairns, Australia. Invited Speaker and Session Chairman. 2001 The 34th International Congress of Physiological Sciences, Christchurch, New Zealand.

Invited Speaker and Organizer of the Synthesium on Physiology of Iron Metabolism. 2001 Second International Workshop on Copper and Iron Homeostasis, Pucon, Chile. 2002 Second International Conference on Biology, Chemistry and Therapeutic Applications of Nitric Oxide (NO 2002), Prague, Czech Republic. 2002 Twelfth International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases (ICOC), Santorini, Greece. 2002 VIth Conference of the International Society for Trace Elements in Humans, Quebec

City, Canada. 2002 Czech and Slovak Congress of Hematology (with International Participation), Prague,

Czech Republic. 2002 International Conference on Molecular and Clinical Aspects of Human Iron Metabolism,

Benedictine’s Abbey, Frauenimsel, Lake Chiemsee, Bavaria, Germany. 2003 Thirteenth International Conference on Oral Chelation in the Treatment of Thalassemia

and Other Diseases (ICOC), Prague, Czech Republic. Keynote Speaker and Session Chairman.

2003 International Conference on Heme Oxygenase, Uppsala, Sweden. 2004 Fourth Scientific Meeting of the Oxidative Stress Consortium, University of Toronto,

Toronto, Ont. 2004 Twenty-Second World Congress of Czechoslovak Society of Arts and Sciences, Palacky

University, Olomouc, Czech Republic. 2004 Seventh International Symposium on Chelating Agents in Biomedicine, Toxicology and

Therapeutics, Pilsen, Czech Republic. Keynote Speaker and Session Chairman. 2004 The Australian Health and Medical Research Congress, Sydney, NSW.


51

2005 Thirty-Seventh European Metabolic Group Meeting, Prague, Czech Republic. 2005 The Third International Symposium on Natural Antioxidants – Molecular Mechanisms

and Health Effects (ISNA) and a Meeting of the Society for Free Radical Research (SFRR Asia), Shanghai, China (presented by Dr. Guangjun Nie, PDF).

2005 The Third Joint Meeting of the Society for Free Radical Research of Australia and Japan,

Griffith University, Gold Coast, Queensland, Australia. 2006 Workshop on “Gaseous Signaling in Health and Disease”, European Society for Clinical

Investigation Meeting, Prague, Czech Republic. 2006 Minisymposium on “Metals in Blood”, Centre for Blood Research, University of British

Columbia, Vancouver, B.C. 2006 Sixteenth International Conference on Chelation in the Treatment of Thalassaemia,

Cancer and Other Diseases of Metal and Free radical Damage and Toxicity, Limassol, Cyprus.

2006 The Scientific Committee Session on Iron and Heme, Forty-Eight Annual Meeting of the

American Society of Hematology, Orlando, Florida. 2007 Biolron 2007 Congress, Kyoto, Japan: Session Chairman. 2007 “Porphyrins and Porphyrias 2007, Rotterdam, The Netherlands: Keynote Speaker and

Session Chairman. 2007 The Fifth International Congress on Heme Oxygenases, Krakow, Poland.

2008 The First International Conference RAHMS: Recent Advances in Health and Medical

Sciences, Paphos, Cyprus.

B. Lectures (L) or Posters (P) Presented at Various Conferences, Mostly International 1967- Annual Meetings of Czechoslovak Physiological and Hematological 1978 Societies. 1967 Fourth Annual Meeting of the Federation of European Biochemical Societies (L), Oslo,

Norway. 1967 Conference on Erythrocyte Metabolism (L), Berlin, East Germany. 1968 Fifth Annual Meeting of the Federation of European Biochemical Societies (L), Prague,

Czechoslovakia. 1969 Sixth Annual Meeting of the Federation of European Biochemical Societies (2P), Madrid,

Spain.


52

1970 International Conference on the Regulation of Erythropoiesis and Hemoglobin Synthesis (L), Prague, Czechoslovakia.

1971 Annual Meeting of the Hungarian Society of Hematology (L), Budapest, Hungary. 1973 Conference on Erythrocyte Metabolism (L), Berlin, East Germany. 1975 Second International Conference on Proteins of Iron Storage and Transport (L), Louvaila-

Neuve, Belgium. 1975 Symposium on Stem Cell Proliferation and Differentiation (L), Prague, Czechoslovakia. 1977 Third International Conference on Proteins of Iron Storage and Transport (L), Arden House, Harriman, New York. 1978 Twelfth Annual Meeting of the Federation of European Biochemical Societies (2P),

Dresden, East Germany. 1978 Seventeenth Congress of the International Society of Hematology (P), Paris, France. 1980 ICN-UCLA Conference on Cellular Development and Differentiation (P) and

participation in a workshop on Specific Gene Products at that conference, Keystone, Colorado.

1980 Second Conference on Hemoglobin Switching (P), Airlie House, Virginia. 1980 Symposium on Iron Overload, Co-organizer and Chairman of the Session on

"Pathogenesis of Iron Overload", Montreal, Canada. 1980 Eighteenth Congress of the International Society of Hematology (2P) and Chairmanship

of the session on "Iron Absorbtion and Kinetics", Montreal, Canada. 1980 Second Symposium on Development of Iron Chelators for Clinical Use (P), San

Francisco, California. 1981 Canadian Physiological Society (L), St. Adele, Quebec, Canada. 1981 Canadian Federation of Biological Societies, Workshop on Erythropoiesis (L), Montreal,

Quebec, Canada. 1981 Fifth International Conference on Proteins of Iron Storage and Transport (2), San Diego,

California. 1981 International Symposium on Cellular and Molecular Biology of Hemopoietic Stem Cell

Differentiation (P), Honey Harbor, Ontario, Canada.


53

1981 Twenty-third Annual Meeting of the American Society of Hematology (L), San Antonio, Texas.

1982 Canadian Federation of Biological Societies (L), Edmonton, Alberta, Canada. 1982 Gordon Research Conference on Chemistry and Biology of Pyrrole Compounds (P),

Brewster Academy, Wolfeboro, New Hampshire. 1982 Twenty-Fourth Annual Meeting of the American Society of Hematology (P), Washington, D.C. 1983 Gordon Research Conference on Red Cells (2P), Plymouth, New Hampshire. 1984 Red Cell Club Meeting (L), Montreal, Quebec, Canada. 1984 Twenty-Sixth Annual Meeting of the American Society of Hematology (2L), Miami

Beach, Florida. 1985 Seventh International Conference on Proteins of Iron Metabolism (3P), Lille, France. 1985 First International Symposium on Iron Transport-Storage-Metabolism (L), Tubingen,

West Germany. 1985 Gordon Research Conference on Red Cells (L), Plymouth, New Hampshire. 1985 Twenty-Seventh Annual Meeting of the American Society of Hematology (1L,1P), New

Orleans, Louisiana. 1986 Twenty-Eighth Annual Meeting of the American Society of Hematology (2P), San

Francisco, California. 1987 Eighth International Conference on Proteins of Iron Transport and Storage (3P), Le

Chateau Montebello, Quebec. 1987 European Iron Club Meeting (1L,1P), Glasgow, U.K. 1989 UCLA Symposium on Hematopoiesis (P), Tamarron, Colorado. 1990 Meeting on Cooperation in Education and Research between Czech and Slovak

Federative Republic and Canada, Stirin, Czechoslovakia. 1992 Keystone Symposium on Hematopoiesis (P), Tamarron, Colorado. 1992 Thirty-Fourth Annual Meeting of the American Society of Hematology (1L,1P),

Anaheim, CA. 1993 Canadian Physiological Society Meeting (L), Mont Tremblant, Quebec.


54

1993 Gordon Research Conference on Red Cells (P), Plymouth, New Hampshire. 1993 Thirty-Fifth Annual Meeting of the American Society of Hematology (3P), St. Louis,

MO. 1994 Fourth European Congress of Cell Biology (P), Prague, Czech Republic. 1995 Thirty-Seventh Annual Meeting of the American Society of Hematology (2P), Seattle,

WA. 1996 Gordon Research Conference on Chemistry and Biology of Tetrapyrroles (P), New

England College, Henniker, New Hampshire. 1997 Tenth Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias

and Lymphomas (1P), Hamburg, Germany. 1997 Thirty-Ninth Annual Meeting of the American Society of Hematology (4P), San Diego,

California. 1998 Third International Conference on Biochemistry and Molecular Biology of Nitric Oxide

(1P), Los Angeles, California. 1998 Twenty-Seventh Annual Meeting of the International Society of Experimental

Hematology (1L), Vancouver, BC. 1998 Fortieth Annual Meeting of the American Society of Hematology (2P), Miami Beach,

Florida. 1999 Twenty-Eighth Annual Meeting of the International Society for Experimental

Hematology (1L), Monte Carlo, Monaco.

1999 Forty-First Annual Meeting of the American Society of Hematology (3P), New Orleans, Louisiana.

2000 Forty-Second Annual Meeting of the American Society of Hematology (1L,1P), San

Francisco, California. 2001 Forty-Third Annual Meeting of the American Society of Hematology (1L, 1P), Orlando, Florida. 2002 Third International Biometals Symposium (1L,1P), London, U.K. 2003 Thirty-First Annual Meeting of the International Society for Experimental Hematology

(1L,1P), Montreal, QC, Canada. 2003 Experimental Biology 2003, San Diego, California (1L).


55

2003 Thirty-Second Annual Meeting of the International Society of Experimental Hematology, Paris, France (1L).

2003 Forty-Fifth Annual Meeting of the American Society of Hematology, San Diego,

California (1L, 3P). 2004 Twelfth International Congress of Immunology and Fourth Annual Conference of

FOCIS, Montreal, QC (1L). 2004 Forty-Sixth Annual Meeting of the American Society of Hematology, San Diego,

California (5P). 2005 Forty-Seventh Annual Meeting of the American Society of Hematology, Atlanta, Georgia

(3P). 2006 Forty-Eight Annual Meeting of the American Society of Hematology, Orlando, Florida

(L). 2007. Forty-Ninth Annual Meeting of the American Society of Hematology, Atlanta, Georgia (1L, 1P). C. Seminars 1968- Seminars in various Departments of Faculty of Medicine, Charles University, Prague, 1978 Czechoslovakia. 1975 Division of Hematology, University of Ulm, Ulm/Donau, Germany. 1977 Rockefeller University, New York, New York. 1977 Cardeza Foundation of Hematological Research, Thomas Jefferson University,

Philadelphia, Pennsylvania. 1977 Department of Clinical Chemistry, University of Bergen, Bergen, Norway. 1979 McGill Cancer Centre, Montreal, Quebec, Canada. 1979 Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts. 1980 Department of Immunology and Microbiology, McGill University, Montreal, Quebec,

Canada. 1980 Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis -

Jewish General Hospital, Montreal, Quebec, Canada. 1980 Guest Lecturer in Dr. Robert Gallo's Laboratory, National Institutes of Health, Bethesda,

Maryland.


56

1981 Department of Physiology, McGill University, Montreal, Quebec, Canada. 1981 Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis - Jewish General

Hospital, Montreal, Quebec, Canada. 1981 Division of Hematology, Royal Victoria Hospital, Montreal, Quebec, Canada. 1981 Department of Biology, Universidad Autonoma Nacional de Mexico, Mexico City

(Series of 5 seminars on Erythropoiesis, Hemoglobin Synthesis and Iron Metabolism). 1982 Division of Immunology, Montreal General Hospital Research Institute, Montreal,

Quebec, Canada. 1982 Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis -

Jewish General Hospital, Montreal, Quebec, Canada. 1983 First Department of Internal Medicine, University of Nagoya, Nagoya, Japan. 1983 Third Department of Internal Medicine, University of Tokyo, Tokyo, Japan. 1983 Department of Biochemistry, State University of New York at Buffalo, New York. 1984 Department of Anatomy, McGill University, Montreal, Quebec, Canada. 1984 Department of Biochemistry, University of Vermont, Burlington, Vermont. 1985 Department of Medicine, University of Utah, Salt Lake City, Utah. 1987 Department of Medicine, University of Utah, Salt Lake City, Utah. 1987 Department of Haematology, Royal Postgraduate Medical School, Hammersmith

Hospital, London, U.K. 1988 Swiss Institute for Experimental Cancer Research, Epalinges s./Lausanne, Switzerland. 1988 Laboratoire de Génétique Moléculaire, Faculté de Médecine Xavier Bichat, Université

Paris - 7, Paris, France. 1988 Department of Transfusion Medicine, University of Ulm, Ulm/Donau, West Germany. 1988 Department of Haematology, Faculty of Medicine, State University of Utrecht, Utrecht,

The Netherlands. 1988 Institut de Topologie et de Dynamique des Systèmes, Université Paris-7, Paris, France.


57

1988 Division of Hematology/Oncology, Department of Medicine, University of Alabama in Birmingham, Birmingham, Alabama.

1989 Department of Biochemistry, McGill University, Montreal, Quebec. 1990 Department of Anatomy, McGill University, Montreal, Quebec. 1990 Division of Hematology, Royal Victoria Hospital, Montreal, Quebec. 1990 Institute of Haematology and Blood Transfusion, Prague, Czechoslovakia. 1990 Institute of Molecular Pathology, Vienna, Austria. 1991 Department of Chemistry and Biochemistry, Concordia University, Montreal, Quebec. 1991 Department of Physiology, University of Ottawa, Ottawa, Ontario. 1991 The Variety Research Centre and the Department of Pediatrics, University of British

Columbia, Vancouver, B.C. 1991 Department of Biochemistry, University of British Columbia, Vancouver, B.C. 1991 Division of Haematology, University Hospital-Shaughnessy Site, Vancouver, B.C. 1992 Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec. 1992 Merck Frosst Centre for Therapeutic Research. Merck Frosst Canada, Pointe Claire,

Quebec. 1992 Laboratory of Chemical Biology, National Institutes of Health, Bethesda, Maryland. 1993 Department of Pediatrics, Hôpital Ste-Justine, Montreal, Quebec. 1993 Department of Medicine, University of Utah, Salt Lake City, Utah. 1993 Institut du Cancer de Montréal, l'Hôpital Notre-Dame, Montreal, Quebec. 1994 Department of Medicine, University of Utah, Salt Lake City, Utah: Visiting Professor. 1994 Department of Physiology and Biophysics, Albert Einstein College of Medicine of

Yeshiva University, Bronx, New York. 1994 Ciba-Geigy, Basel, Switzerland. 1995 Department of Biochemistry, University of Vermont, Burlington, VT. 1995 Department of Medicine, University of Utah, Salt Lake City, Utah: Visiting Professor.


58

1995 Hôpital Sainte-Justine, Centre de recherche, Montreal, QC. 1996 Howard Hughes Medical Institute, The Children's Hospital, Harvard Medical School,

Boston, Massachusetts. 1996 Department of Hematology, Western Infirmary, University of Glasgow, Glasgow,

Scotland. 1996 Faculty of Medicine, Charles University, Prague, Czech Republic (Series of Seminars on

Iron Metabolism, Heme Synthesis and Nitric Oxide). 1996 Ciba-Geigy, Basel, Switzerland. 1997 Department of Biochemistry, The University of Texas, San Antonio, Texas. 1997 Department of Medicine, Third Faculty of Medicine, Charles University, Prague, Czech

Republic. 1997 Department of Biochemistry, The University of Georgia, Athens, Georgia. 1997 Institute of Molecular Pathology, University of Vienna, Vienna, Austria. 1998 Faculty of Medicine, The University of Western Australia, Perth, WA, Australia: Raine

Visiting Professors' Lecture Series. 1998 Department of Chemistry, Murdoch University, Perth, WA, Australia. 1998 Department of Physiology, The University of Western Australia, Perth, WA, Australia. 1998 Heart Research Institute, The University of Sydney, Sydney, NSW, Australia. 1998 Queensland Institute for Medical Research, The University of Queensland, Brisbane,

Queensland, Australia. 1998 School of Biological Sciences, The University of Auckland, Auckland, New Zealand. 1998 Department of Anatomy, The National University of Singapore, Singapore. 1998 Institute of Science and Technology for Research and Development, Mahidol University,

Bangkok, Thailand. 1998 Department of Anatomy, Seoul National University, College of Medicine, Seoul, Korea. 1998 Department of Medicine, Yonsei University School of Medicine, Seoul, Korea. 1998 Department of Hygiene, Kansai Medical University, Moriguchi, Osaka, Japan


59

1999 First Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.

1999 Department of Cell Biology, Phillips University, Marburg, Germany. 1999 Institute of Hematology and Blood Transfusion, Prague, Czech Republic. 2000 Department of Pathophysiology, Faculty of Medicine, Charles University, Prague, CR. 2000 Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan. 2000 Department of Biotechnology, Kyoto Institute of Technology, Kyoto, Japan. 2000 Division of Integrated Life Science, Graduate School of Biostudies, Kyoto University,

Kyoto, Japan. 2000 Children’s Hospital, Oakland Research Institute, Oakland, California. 2001 Clinical Nutrition Research Unit, Vanderbilt University Medical Center, Nashville,

Tennessee. 2001 Department of Medicine, Third Faculty of Medicine, Charles University, Prague, Czech

Republic. 2001 Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Kralove,

Czech Republic. 2001 Oxidative Stress Consortium Meeting, London, Ontario. 2001 Marine Biological Laboratory, Woods Hole, MA, U.S.A. 2001 Heart Research Institute, The University of Sydney, Sydney, NSW, Australia. 2001 Département de Chimie et de biochemie, Université du Québec à Montréal, Montréal,

Québec. 2001 Grey Bruce Health Services, Owen Sound, Ontario. 2002 Institute of Medical Biochemistry, Division of Molecular Biology, Vienna Biocenter,

Vienna, Austria. 2002 Department of Medicine, Third Faculty of Medicine, Charles University, Prague, Czech

Republic. 2003 Department of Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech

Republic.


60

2003 Department of Biochemistry, Faculty of Medicine, Charles University, Prague, Czech Republic.

2005 Baylor College of Medicine, Houston, Texas. 2005 Department of Pediatrics and Adolescent Medicine, Charles University Faculty of

Medicine, Prague, Czech Republic. 2006 Physiological Institute, Czech Academy of Sciences, Prague, Czech Republic. 2007 GSF – Institute of Molecular Biology and Tumor Genetics, National Research Center for

Environment and Health, Munic, Germany. 2007 James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky. 2008 Department of Pharmacology and Toxicology Dartmouth Medical School, Hannover,

New Hampshire. D. Service on Editorial Boards

Redox Report Journal of Trace Elements in Experimental Medicine Guest Editor for a special issue on “New Developments in Iron Metabolism and Implications in Disease” for TheScientificWorldJournal

E. Manuscript Review Regular reviewer: American Journal of Hematology

Biochemical Pharmacology Biochimica et Biophysica Acta Blood

European Journal of Biochemistry / FEBS Journal FEBS Letters International Journal of Biochemistry and Cell Biology Journal of Laboratory and Clinical Medicine / Translational Research Occasional reviewer: American Journal of Physiology American Journal of Respiratory Cell and Molecular Biology

Analytical Biochemistry Archives of Biochemistry and Biophysics Biochemical Journal

Biochemistry and Cell Biology Biorheology Cancer Research Carcinogenesis Cardiovascular Research Cell Cell and Tissue Kinetics


61

E. Manuscript Reviewer (continued) Clinical and Investigative Medicine

Clinical Chemistry Clinical Chemistry and Laboratory Medicine (CCLM)

Chemical Research in Toxicology Critical Reviews in Clinical and Laboratory Sciences

Critical Reviews in Oncology Hematology Development Experimental Hematology European Journal of Clinical Investigation

European Journal of Pharmacology European Respiratory Journal

Journal of Molecular Biology Experimental and Molecular Pathology Free Radical Biology and Medicine

Gene Gut

Haematologica Human Molecular Genetics JAMA Journal of Applied Physiology Journal of Biological Chemistry Journl of Cellular Biochemisty Journal of Cellular Physiology Journal of Clinical Investigation Journal of Leukocyte Biology Journal of Medicinal Chemistry Journal of Molecular Biology Journal of Neurochemistry Journal of Nuclear Medicine Journal of The Chemical Society of Pakistan Journal of Theoretical Biology Kidney International Lancet Molecular Cancer Therapeutics Molecular Cell Molecular and Cellular Biochemistry Molecular and Cellular Biology Molecular Pharmacology Nature New England Journal of Medicine Neuroreport Nitric Oxide: Biology and Chemistry Pediatric Research Pharmacological Reviews Physiological Genomics


62

Proceedings of the National Academy of Sciences USA The American Journal of Medical Sciences The Journal of Pharmacology and Experimental Therapeutics

Documents

PREM PONKA CURRICULUM VITAE - Univerzita Karlova · PREM PONKA CURRICULUM VITAE Place of Birth: Prague, Czechoslovakia Matial Status: Married, 2 children Citizenship: Canadian EDUCATION